

ARRAY BIOPHARMA INC
Form 10-Q
May 03, 2011
Table of Contents

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2011

or

TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-16633

Array BioPharma Inc.

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

(Exact Name of Registrant as Specified in Its Charter)

Delaware

*(State or Other Jurisdiction of
Incorporation or Organization)*

84-1460811

(I.R.S. Employer Identification No.)

3200 Walnut Street, Boulder, CO

(Address of Principal Executive Offices)

80301

(Zip Code)

(303) 381-6600

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer, and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer Accelerated Filer

Non-Accelerated Filer Smaller Reporting Company

(do not check if smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of April 28, 2011, the registrant had 57,020,003 shares of common stock outstanding.

Table of Contents

ARRAY BIOPHARMA INC.
QUARTERLY REPORT ON FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED MARCH 31, 2011

TABLE OF CONTENTS

	<u>Page No.</u>
<u>PART I</u>	
	<u>FINANCIAL INFORMATION</u>
<u>Item 1.</u>	1
	<u>Condensed Financial Statements (unaudited)</u>
	1
	<u>Condensed Balance Sheets as of March 31, 2011 and June 30, 2010</u>
	1
	<u>Condensed Statements of Operations and Comprehensive Loss for the</u>
	<u>three and nine months ended March 31, 2011 and 2010</u>
	2
	<u>Condensed Statement of Stockholders' Deficit for the nine months ended</u>
	<u>March 31, 2011</u>
	3
	<u>Condensed Statements of Cash Flows for the nine months ended</u>
	<u>March 31, 2011 and 2010</u>
	4
	<u>Notes to the Unaudited Condensed Financial Statements</u>
	5
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results</u>
	<u>of Operations</u>
	27
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u>
<u>Item 4.</u>	<u>Controls and Procedures</u>
	41
	42
<u>PART II</u>	
	<u>OTHER INFORMATION</u>
<u>Item 1.</u>	<u>Legal Proceedings</u>
	43
<u>Item 1A.</u>	<u>Risk Factors</u>
	43
<u>Item 2.</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>
	46
<u>Item 3.</u>	<u>Defaults Upon Senior Securities</u>
	46
<u>Item 4.</u>	<u>Reserved</u>
	46
<u>Item 5.</u>	<u>Other Information</u>
	46
<u>Item 6.</u>	<u>Exhibits</u>
	47
<u>SIGNATURES</u>	48
<u>EXHIBIT INDEX</u>	
Certification of CEO Pursuant to Section 302	49
Certification of CFO Pursuant to Section 302	50
Certification of CEO and CFO Pursuant to Section 906	51

Table of Contents**PART I. FINANCIAL INFORMATION****ITEM 1. CONDENSED FINANCIAL STATEMENTS****ARRAY BIOPHARMA INC.****Condensed Balance Sheets**

(Amounts in Thousands, Except Share and Per Share Amounts)

(Unaudited)

	March 31, 2011	June 30, 2010
ASSETS		
Current assets		
Cash and cash equivalents	\$ 37,354	\$ 32,846
Marketable securities	37,954	78,664
Prepaid expenses and other current assets	16,836	5,788
Total current assets	92,144	117,298
Long-term assets		
Marketable securities	527	17,359
Property and equipment, net	18,366	21,413
Other long-term assets	2,682	3,109
Total long-term assets	21,575	41,881
Total assets	\$ 113,719	\$ 159,179
LIABILITIES AND STOCKHOLDERS DEFICIT		
Current liabilities		
Accounts payable	\$ 4,929	\$ 5,634
Accrued outsourcing costs	4,631	4,907
Accrued compensation and benefits	6,774	10,013
Other accrued expenses	1,956	1,723
Deferred rent	3,295	3,180
Deferred revenue	51,566	52,474
Current portion of long-term debt	150	-
Total current liabilities	73,301	77,931
Long-term liabilities		
Deferred rent	15,804	18,301
Deferred revenue	47,544	65,177
Long-term debt, net	117,650	112,825
Other long-term liabilities	3,566	1,623
Total long-term liabilities	184,564	197,926
Total liabilities	257,865	275,857
Commitments and contingencies		
Stockholders deficit		

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Preferred stock, \$0.001 par value; 10,000,000 shares authorized, no shares issued or outstanding	-	-
Common stock, \$0.001 par value; 120,000,000 shares authorized; 56,555,553 and 53,224,248 shares issued and outstanding, as of March 31, 2011 and June 30, 2010, respectively	57	53
Additional paid-in capital	344,902	332,277
Warrants	36,296	36,296
Accumulated other comprehensive income	3	5,528
Accumulated deficit	(525,404)	(490,832)
Total stockholders deficit	(144,146)	(116,678)
Total liabilities and stockholders deficit	\$ 113,719	\$ 159,179

The accompanying notes are an integral part of these condensed financial statements.

Table of Contents**ARRAY BIOPHARMA INC.****Condensed Statements of Operations and Comprehensive Loss**

(Amounts in Thousands, Except Per Share Data)

(Unaudited)

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2011	2010	2011	2010
Revenue				
Collaboration revenue	\$ 3,934	\$ 5,396	\$ 15,024	\$ 14,874
License and milestone revenue	13,907	12,980	37,831	21,036
Total revenue	17,841	18,376	52,855	35,910
Operating expenses				
Cost of revenue	6,617	7,946	21,281	19,103
Research and development for proprietary programs	15,883	17,692	44,219	55,997
General and administrative	3,795	4,264	11,969	12,938
Total operating expenses	26,295	29,902	77,469	88,038
Loss from operations	(8,454)	(11,526)	(24,614)	(52,128)
Other income (expense)				
Realized gains on auction rate securities, net	1,093	357	1,891	1,304
Interest income	31	164	391	726
Interest expense	(4,172)	(4,152)	(12,240)	(11,685)
Total other expenses, net	(3,048)	(3,631)	(9,958)	(9,655)
Net loss	\$ (11,502)	\$ (15,157)	\$ (34,572)	\$ (61,783)
Change in unrealized gains and losses on marketable securities	(4,304)	711	(5,525)	2,699
Comprehensive loss	\$ (15,806)	\$ (14,446)	\$ (40,097)	\$ (59,084)
Weighted average shares outstanding - basic and diluted	56,129	50,697	54,934	49,403
Net loss per share - basic and diluted	\$ (0.20)	\$ (0.30)	\$ (0.63)	\$ (1.25)

The accompanying notes are an integral part of these condensed financial statements.

Table of Contents**ARRAY BIOPHARMA INC.****Condensed Statement of Stockholders Deficit**

(Amounts in Thousands)

(Unaudited)


	Preferred Shares	Stock Amounts	Common Shares	Stock Amounts	Additional Paid-in Capital	Warrants	Accumulated Other Comprehensive Income	Accumulated Deficit	Total
Balance as of June 30, 2010	-	\$ -	53,224	\$ 53	\$ 332,277	\$ 36,296	\$ 5,528	\$ (490,832)	\$ (116,678)
Issuance of common stock under stock option and employee stock purchase plans	-	-	606	1	1,490	-	-	-	1,491
Share-based compensation expense	-	-	-	-	2,770	-	-	-	2,770
Issuance of common stock for cash, net of offering costs	-	-	1,445	2	4,384	-	-	-	4,386
Payment of employee bonus with stock	-	-	1,280	1	3,981	-	-	-	3,982
Reclassification of unrealized gain out of accumulated other comprehensive income to earnings	-	-	-	-	-	-	(2,705)	-	(2,705)
Change in unrealized gain on marketable securities	-	-	-	-	-	-	(2,820)	-	(2,820)
Net loss	-	-	-	-	-	-	-	(34,572)	(34,572)
Balance as of March 31, 2011	-	\$ -	56,555	\$ 57	\$ 344,902	\$ 36,296	\$ 3	\$ (525,404)	\$ (144,146)

The accompanying notes are an integral part of these condensed financial statements.

Table of Contents

ARRAY BIOPHARMA INC.
Condensed Statements of Cash Flows
(Amounts in Thousands)
(Unaudited)

Nine Months Ended March 31,
2011 **2010**



The accompanying notes are an integral part of these condensed financial statements.

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

NOTE 1 - OVERVIEW AND BASIS OF PRESENTATION

Organization

Array BioPharma Inc. (the Company) is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. The Company's proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, leading pharmaceutical and biotechnology companies partner with the Company to discover and develop drug candidates across a broad range of therapeutic areas.

Basis of Presentation

The Company follows the accounting guidance outlined in the Financial Accounting Standards Board Codification. The accompanying unaudited Condensed Financial Statements have been prepared without audit and do not include all of the disclosures required by the Financial Accounting Standards Board Codification guidelines, which have been omitted pursuant to the rules and regulations of the Securities and Exchange Commission (SEC) relating to requirements for interim reporting. The year-end condensed balance sheet data was derived from audited financial statements but does not include all disclosures required by accounting principles generally accepted in the United States (U.S.). The unaudited Condensed Financial Statements reflect all adjustments (consisting only of normal recurring adjustments) that, in the opinion of management, are necessary to present fairly the financial position of the Company as of March 31, 2011, its results of operations for the three and nine months ended March 31, 2011 and 2010, and its cash flows for the nine months ended March 31, 2011 and 2010. Operating results for the nine months ended March 31, 2011 are not necessarily indicative of the results that may be expected for the year ending June 30, 2011.

These unaudited Condensed Financial Statements should be read in conjunction with the Company's audited Financial Statements and the notes thereto included in the Company's Annual Report on Form 10-K for the year ended June 30, 2010 filed with the SEC on August 12, 2010.

Certain fiscal 2010 amounts have been reclassified to conform to the current year presentation. Specifically, Derivative Liabilities is now included in Other Long-term Liabilities in the accompanying Condensed Balance Sheets. Additionally, all gains and losses related to auction rate securities (ARS) in the Condensed Statements of Operations and Comprehensive Loss are included in

Realized Gains on Auction Rate Securities, Net, whereas they were previously recorded in Interest Income and Impairment of Marketable Securities, respectively.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the U.S. requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenue and expenses during the reporting period. Although management bases these estimates on historical data and other assumptions believed to be reasonable under the circumstances, actual results could differ significantly from these estimates.

The Company believes the accounting estimates having the most significant impact on its financial statements relate to (i) estimating the periods over which up-front and milestone payments from collaboration agreements are recognized; (ii) estimating accrued outsourcing costs for clinical trials and preclinical testing; and (iii) estimating the fair value of the Company's long-term debt that has associated warrants and embedded derivatives, and the separate valuation of those warrants and embedded derivatives.

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

Liquidity

The Company has incurred operating losses and has an accumulated deficit as a result of ongoing research and development spending. As of March 31, 2011, the Company had an accumulated deficit of \$525.4 million. The Company had net losses of \$11.5 million and \$34.6 million for the three and nine months ended March 31, 2011, respectively, and \$77.6 million, \$127.8 million and \$96.3 million for the fiscal years ended June 30, 2010, 2009 and 2008, respectively.

The Company has historically funded its operations from up-front fees and license and milestone revenue received under its collaborations and out-licensing transactions, from the issuance and sale of its equity securities and through debt provided by its credit facilities. For example, the Company has received \$119.5 million in the last eighteen months, including the following payments under its collaborations:

- In December 2009, the Company received a \$60 million up-front payment from Amgen Inc. under a Collaboration and License Agreement
- In April 2010, the Company received \$45 million in an up-front and milestone payment under a License Agreement with Novartis Pharmaceutical International Ltd.
- In December 2010, the Company received \$10 million in a milestone payment under a License Agreement with Celgene Corporation.

The recognition of revenue under these agreements is discussed further in *Note 4 Deferred Revenue*. However, until the Company can generate sufficient levels of cash from its operations, which the Company does not expect to achieve in the foreseeable future, the Company will continue to utilize its existing cash, cash equivalents and marketable securities.

The Company uses approximately \$20 million per quarter to fund its operations. The Company believes that the cash, cash equivalents and marketable securities it holds as of March 31, 2011, will enable it to continue to fund its operations for at least the next 12 months assuming the Company continues to obtain funding through up-front fees from new out-licensing transactions and milestone payments from new and/or existing collaborations. The ability to continue to fund ongoing operations also assumes that the Company will continue to satisfy its interest payment obligations under the credit facilities with Deerfield Private Design Fund, L.P. and Deerfield Private Design International Fund, L.P. (who are referred to collectively as Deerfield) with the proceeds from sales of its common stock pursuant to the Equity Distribution Agreement with Piper Jaffray & Co. discussed in *Note 8 Equity Distribution Agreement* or through the issuance of shares of common stock to Deerfield in accordance with the Company's Facility Agreements with Deerfield. The Company may also fund operations through the sale of its equity securities. Although the Company is currently in active licensing discussions with a number of potential partners on select programs, there can be no assurance that the Company will successfully close new collaborations that provide for up-front fees. Furthermore, sufficient funds

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

may not continue to be available to the Company when needed from existing or future collaborations or from the proceeds of debt or equity financings.

If the Company is unable to obtain additional funding from these or other sources when needed or to the extent needed, it may be necessary to significantly reduce its current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient funds may also require the Company to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to it or its stockholders than the Company would otherwise choose in order to obtain up-front license fees needed to fund its operations.

Fair Value Measurements

The Company's financial instruments are recognized and measured at fair value in the Company's financial statements and primarily consist of cash and cash equivalents, marketable securities, long-term investments, trade receivables and payables, long-term debt, embedded derivatives associated with the

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

long-term debt and warrants. The Company uses different valuation techniques to measure the fair value of assets and liabilities, as discussed in more detail below. Fair value is defined as the price that would be received or paid to sell the financial instruments in an orderly transaction between market participants at the measurement date. The Company uses a framework for measuring fair value based on a hierarchy that distinguishes sources of available information used in fair value measurements and categorizes them into three levels:

- Level I: Quoted prices in active markets for identical assets and liabilities.
- Level II: Observable inputs other than quoted prices in active markets for identical assets and liabilities.
- Level III: Unobservable inputs.

The Company discloses assets and liabilities measured at fair value based on their level in the hierarchy. Considerable judgment is required in interpreting market and other data to develop estimates of fair value for assets or liabilities for which there are no quoted prices in active markets, which include the Company's ARS, warrants issued by the Company in connection with its long-term debt and the embedded derivatives associated with the long-term debt. The use of different assumptions and/or estimation methodologies may have a material effect on their estimated fair value. Accordingly, the fair value estimates disclosed by the Company may not be indicative of the amount that the Company or holders of the instruments could realize in a current market exchange.

The Company periodically reviews the realizability of each investment when impairment indicators exist with respect to the investment. If an other-than-temporary impairment of the value of an investment is deemed to exist, the cost basis of the investment is written down to its then estimated fair value.

Cash and Cash Equivalents

Cash equivalents consist of short-term, highly liquid financial instruments that are readily convertible to cash and have maturities of 90 days or less from the date of purchase and may consist of money market funds, taxable commercial paper, U.S. government agency obligations and corporate notes and bonds with high credit quality.

Marketable Securities

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

The Company has designated its marketable securities as of each balance sheet date as available-for-sale securities and accounts for them at their respective fair values. Marketable securities are classified as short-term or long-term based on the nature of these securities and the availability of these securities to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying Condensed Balance Sheets. Marketable securities that are not considered available for use in current operations (including when active markets for such securities do not exist) are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying Condensed Balance Sheets.

Securities that are classified as available-for-sale are carried at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of Stockholders' Deficit until their disposition. The Company reviews all available-for-sale securities each period to determine if they remain available-for-sale based on the Company's then current intent and ability to sell the security if it is required to do so. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in Interest Income in the accompanying Condensed Statements of Operations and Comprehensive Loss. Realized gains and losses on ARS along with declines in value judged to be other-than-temporary are reported in Realized Gains on Auction Rate Securities, Net in the accompanying Condensed Statements of Operations and

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

Comprehensive Loss when recognized. The cost of securities sold is based on the specific identification method.

The Company sold its remaining ARS during the quarter ended March 31, 2011. Prior to their disposition, the Company determined the carrying value of the ARS under the fair value hierarchy using Level III, or unobservable inputs, as there was no active market for the securities. The most significant unobservable inputs used in this method are estimates of the amount of time until a liquidity event will occur and the discount rate, which incorporates estimates of credit risk and a liquidity premium (discount). Due to the inherent complexity in valuing these securities, the Company engaged a third-party valuation firm to perform an independent valuation of the ARS as part of the Company's overall fair value analysis beginning with the first quarter of fiscal 2009 and continuing through the quarter ended December 31, 2010. While the Company believes that the estimates used historically in the fair value analysis are reasonable, a change in any of the assumptions underlying these estimates would have resulted in different fair value estimates that could have resulted in additional adjustments to the ARS for prior periods, either increasing or further decreasing their carrying value, possibly by material amounts.

See *Note 3 Marketable Securities* for additional information about the Company's investments in ARS.

Property and Equipment

Property and equipment are stated at historical cost less accumulated depreciation and amortization. Additions and improvements are capitalized. Certain costs to internally develop software are also capitalized. Maintenance and repairs are expensed as incurred.

Depreciation and amortization are computed on the straight-line method based on the following estimated useful lives:

Furniture and fixtures	7 years
Equipment	5 years
Computer hardware and software	3 years

The Company depreciates leasehold improvements associated with operating leases on a straight-line basis over the shorter of the expected useful life of the improvements or the remaining lease term.

The carrying value for property and equipment is reviewed for impairment when events or changes in circumstances indicate that the carrying value of the assets may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows from the use of the asset and its eventual disposition is less than its carrying amount.

Equity Investment

The Company has entered into one collaboration and license agreement and may, in the future, enter into additional agreements in which it receives an equity interest as consideration for all or a portion of up-front, license or other fees under the terms of the agreement. The Company reports the value of equity securities received from non-publicly traded companies in which it does not exercise a significant controlling interest at cost as Other Long-term Assets in the accompanying Condensed Balance Sheets. The Company monitors its investment for impairment at least annually and makes appropriate reductions in the carrying value if it is determined that an impairment has occurred, based primarily on the financial condition and near and long-term prospects of the issuer.

Accrued Outsourcing Costs

Substantial portions of the Company's preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively CROs).

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

These CROs generally bill monthly or quarterly for services performed or bill based upon milestone achievement. For preclinical studies, the Company accrues expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. The Company monitors patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to it by the CROs, correspondence with the CROs and clinical site visits. The Company's estimates depend on the timeliness and accuracy of the data provided by its CROs regarding the status of each program and total program spending. The Company periodically evaluates the estimates to determine if adjustments are necessary or appropriate based on information it receives.

Deferred Revenue

The Company records amounts received but not earned under its collaboration agreements as Deferred Revenue, which are then classified as either current or long-term in the accompanying Condensed Balance Sheets based on the period during which they are expected to be recognized as revenue.

Long-term Debt and Embedded Derivatives

The terms of the Company's long-term debt are discussed in detail in *Note 5 Long-term Debt*. The accounting for these arrangements is complex and is based upon significant estimates by management. The Company reviews all debt agreements to determine the appropriate accounting treatment when the agreement is entered into and reviews all amendments to determine if the changes require accounting for the amendment as a modification, or as an extinguishment and new debt. The Company also reviews each long-term debt arrangement to determine if any feature of the debt requires bifurcation and/or separate valuation. These may include hybrid instruments, which are comprised of at least two components ((1) a debt host instrument and (2) one or more conversion features), warrants and other embedded derivatives, such as puts and other rights of the debt holder.

The Company currently has two embedded derivatives related to its long-term debt with Deerfield that were valued at \$461 thousand and \$825 thousand at March 31, 2011 and June 30, 2010, respectively, and are included in Other Long-term Liabilities in the accompanying Condensed Balance Sheets. One of the embedded derivatives is a variable interest rate structure that constitutes a liquidity-linked variable spread feature. The other is a significant transaction contingent put option relating to Deerfield's ability to accelerate the repayment of the debt in the event of certain changes in control of the Company. Such event would occur if the acquirer did not meet certain financial conditions, based on size and credit worthiness. Collectively, they are

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

referred to as the Embedded Derivatives. Under the fair value hierarchy, the Company measures the fair value of the Embedded Derivatives using Level III, or unobservable inputs, as there is no active market for them, and calculates fair value using a combination of a discounted cash flow analysis and the Black-Derman-Toy interest rate model.

The fair value of the variable interest rate structure is based on the Company's estimate of the probable effective interest rate over the term of the Deerfield credit facilities that is based on the Company's cash flow forecasts, which include the Company's expectations of future cash inflows from up-front fees, milestone payments and issuances of equity. The fair value of the put option is based on the Company's estimate of the probability that a change in control that triggers Deerfield's right to accelerate the debt will occur. With those inputs, the fair value of each Embedded Derivative is calculated as the difference between the fair value of the Deerfield credit facilities if the Embedded Derivatives are included and the fair value of the Deerfield credit facilities if the Embedded Derivatives are excluded. Due to the inherent complexity in valuing the Deerfield credit facilities and the Embedded Derivatives, the Company has engaged a third-party valuation firm to perform the valuation as part of its overall fair value analysis. The estimated fair value of the Embedded Derivatives was determined based on management's judgment and assumptions and the use of different assumptions could result in significantly different estimated fair values.

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

The initial fair value of the Embedded Derivatives was recorded as Derivative Liabilities and as Debt Discount in the Company's Condensed Balance Sheets. Changes in the value of the Embedded Derivatives is adjusted quarterly and recorded to Derivative Liabilities in the Condensed Balance Sheets and Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

Warrants that the Company issues in connection with its long-term debt arrangements have been classified as equity. The Company values the warrants at issuance based on a Black-Scholes option pricing model and then allocates a portion of the proceeds under the debt to the warrants based upon their relative fair values. The Warrants are recorded in Stockholders' Equity with the offset to Debt Discount. The Debt Discount is being amortized from the respective draw dates to the end of the term of the Deerfield credit facilities using the effective interest method and recorded as Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

Transaction fees paid in connection with our long-term debt arrangements that qualify for capitalization are recorded as Other Long-Term Assets in the Condensed Balance Sheets and amortized to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss using the effective interest method over the term of the underlying debt agreement.

Income Taxes

The Company accounts for income taxes using the asset and liability method. The Company recognizes the amount of income taxes payable or refundable for the year as well as deferred tax assets and liabilities. Deferred tax assets and liabilities are determined based on the difference between the financial statement carrying value and the tax basis of assets and liabilities and, using enacted tax rates in effect, reflect the expected effect these differences would have on taxable income. Valuation allowances are recorded to reduce the amount of deferred tax assets when, based upon available objective evidence, the expected reversal of temporary differences and projections of future taxable income, management cannot conclude it is more likely than not that some or all of the deferred tax assets will be realized.

Operating Leases

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

The Company has negotiated certain landlord/tenant incentives and rent holidays and escalations in the base price of rent payments under its operating leases. For purposes of determining the period over which these amounts are recognized or amortized, the initial term of an operating lease includes the build-out period of leases, where no rent payments are typically due under the terms of the lease and includes additional terms pursuant to any options to extend the initial term if it is more likely than not that the Company will exercise such options. The Company recognizes rent holidays and rent escalations on a straight-line basis over the initial lease term. The landlord/tenant incentives are recorded as an increase to Deferred Rent in the accompanying Condensed Balance Sheets and amortized on a straight-line basis over the initial lease term. The Company has also entered into two sale-lease back transactions for its facilities in Boulder and Longmont, Colorado, where the consideration received from the landlord is recorded as an increase to Deferred Rent in the accompanying Condensed Balance Sheets and amortized on a straight-line basis over the lease term. Deferred Rent balances are classified as short-term or long-term in the accompanying Condensed Balance Sheets based upon the period when reversal of the liability is expected to occur.

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

Share-Based Compensation

The Company uses the fair value method of accounting for share-based compensation arrangements, which requires that compensation expense be recognized based on the grant date fair value of the arrangement. Share-based compensation arrangements include stock options granted under the Company's Amended and Restated Stock Option and Incentive Plan (the Option Plan) and purchases of common stock by its employees at a discount to the market price under the Company's Employee Stock Purchase Plan (the ESPP).

The estimated grant date fair value of stock options is based on a Black-Scholes option pricing model and is expensed on a straight-line basis over the vesting term. Compensation expense for stock options is reduced for forfeitures, which are estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from those estimates. Compensation expense for purchases under the ESPP is measured based on a Black-Scholes option pricing model and incorporates the estimated fair value of the common stock during each offering period as well as the purchase discount.

Revenue Recognition

Most of the Company's revenue is from the Company's collaborators for research funding, up-front or license fees and milestone payments derived from discovering and developing drug candidates. The Company's agreements with collaboration partners include fees based on annual rates for full-time-equivalent employees (FTEs) working on a program and may also include non-refundable license and up-front fees, non-refundable milestone payments that are triggered upon achievement of specific research or development goals and future royalties on sales of products that result from the collaboration. A small portion of the Company's revenue comes from the sale of compounds on a per-compound basis. The Company reports FTE fees for discovery and the development of proprietary drug candidates that the Company out-licenses as Collaboration Revenue. License and Milestone Revenue is combined and consists of up-front fees and ongoing milestone payments from collaborators that are recognized during the applicable period.

The Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104, *Revenue Recognition* (SAB 104), which establishes four criteria, each of which must be met, in order to recognize revenue for the performance of services or the shipment of products. Revenue is recognized when (a) persuasive evidence of an arrangement exists, (b) products are delivered or services are rendered, (c) the sales price is fixed or determinable and (d) collectability is reasonably assured.

Collaboration agreements that include a combination of discovery research funding, up-front or license fees, milestone payments and/or royalties are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet the separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting in accordance with SAB 104.

The Company recognizes revenue from non-refundable up-front payments and license fees on a straight-line basis over the term of performance under the agreement, which is generally the estimated research or development term. These advance payments are deferred and recorded as Deferred Revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying Condensed Balance Sheets.

When the performance period is not specifically identifiable from the agreement, the Company estimates the performance period based upon provisions contained within the agreement, such as the duration of the research or development term, the existence, or likelihood of achievement of development commitments and any other significant commitments of the Company.

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

Most of the Company's agreements provide for milestone payments. In certain cases, a portion of each milestone payment is recognized as revenue when the specific milestone is achieved based on the applicable percentage of the estimated research or development term that has elapsed to the total estimated research and/or development term. In other cases, when the milestone payment is attributed to future development obligations of the Company, the revenue is recognized on a straight-line basis over the estimated remaining development period. Certain milestone payments are for activities for which there are no future obligations and as a result, are recognized when earned in their entirety.

The Company periodically reviews the expected performance periods under each of its agreements that provide for non-refundable up-front payments and license fees and milestone payments and adjusts the amortization periods when appropriate to reflect changes in assumptions relating to the duration of expected performance periods. Revenue recognition for non-refundable license fees and up-front payments and milestone payments could be accelerated in the event of early termination of programs or alternatively, decelerated, if programs are extended. As such, while changes to such estimates have no impact on its reported cash flows, the Company's reported revenue is significantly influenced by its estimates of the period over which its obligations are expected to be performed.

Cost of Revenue and Research and Development for Proprietary Programs

The Company incurs costs in connection with performing research and development activities which consist mainly of compensation, associated fringe benefits, share-based compensation, preclinical and clinical outsourcing costs and other collaboration-related costs, including supplies, small tools, facilities, depreciation, recruiting and relocation costs and other direct and indirect chemical handling and laboratory support costs. The Company allocates these costs between Cost of Revenue and Research and Development for Proprietary Programs based upon the respective time spent by its scientists on development conducted for its collaborators and for its internal proprietary programs. Cost of Revenue represents the costs associated with research and development, including preclinical and clinical trials, conducted by the Company for its collaborators. Research and Development for Proprietary Programs consists of direct and indirect costs for the Company's specific proprietary programs. The Company does not bear any risk of failure for performing these activities and the payments are not contingent on the success or failure of the research program. Accordingly, the Company expenses these costs when incurred.

Where the Company's collaboration agreements provide for it to conduct research and development and for which the Company's partner has an option to obtain the right to conduct further development and to commercialize a product, the Company attributes a portion of its research and development costs to Cost of Revenue based on the percentage of total programs under the agreement that the Company concludes is likely to continue to be funded by the partner. These costs may not be incurred equally across all programs. In addition, the Company continually evaluates the progress of development activities under these agreements and if

events or circumstances change in future periods that the Company reasonably believes would make it unlikely that a collaborator would continue to fund the same percentage of programs, the Company will adjust the allocation accordingly. See *Note 4 Deferred Revenue*, for further information about the Company's collaborations.

Net Loss per Share

Basic net loss per share is computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. Diluted net loss per share reflects the additional dilution from potential issuances of common stock, such as stock issuable pursuant to the exercise of stock options and warrants issued related to the Company's long-term debt. The treasury stock method is used to calculate the potential dilutive effect of these common stock equivalents. Potentially dilutive shares are excluded from the computation of diluted net loss per share when their effect is anti-dilutive. As a result of the Company's net losses through the date of these Financial Statements, all potentially dilutive securities were anti-dilutive and therefore have been excluded from the computation of diluted net loss per share.

Table of Contents

ARRAY BIOPHARMA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
For the Quarter Ended March 31, 2011
(Unaudited)

Comprehensive Income (Loss)

The Company's comprehensive income (loss) consists of the Company's net losses and adjustments to unrealized gains and losses on investments in available-for-sale marketable securities. The Company had no other sources of comprehensive income (loss) for the periods presented.

NOTE 2 SEGMENTS, GEOGRAPHIC INFORMATION AND SIGNIFICANT COLLABORATORS**Segments**

All operations of the Company are considered to be in one operating segment and, accordingly, no segment disclosures have been presented. The physical location of all of the Company's equipment, leasehold improvements and other fixed assets is within the U.S.

Geographic Information

All of the Company's collaboration agreements are denominated in U.S. dollars. The following table details revenue from collaborators by geographic area based on the country in which collaborators are located or the ship-to destination for the compounds (dollars in thousands):

	Three Months Ended		Nine Months Ended	
	March 31,		March 31,	
	2011	2010	2011	2010
North America	\$ 12,456	\$ 18,310	\$ 41,285	\$ 35,706
Europe	5,381	52	11,555	161

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Asia Pacific	4	14	15	43
	\$ 17,841	\$ 18,376	\$ 52,855	\$ 35,910

Significant Collaborators

The following collaborators contributed greater than 10% of total revenue during the periods set forth below:

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2011	2010	2011	2010
Amgen, Inc.	34%	35%	37%	20%
Novartis International Pharmaceutical Ltd.	30%	-	22%	-
Celgene Corporation	21%	23%	21%	28%
Genentech, Inc.	14%	42%	20%	48%
	99%	100%	100%	96%

The loss of one or more significant collaborators could have a material adverse effect on the Company's business, operating results or financial condition. The Company does not require collateral to secure the payment obligations of its collaborators. Although the Company is impacted by economic conditions in the biotechnology and pharmaceutical sectors, most collaborators pay in advance and management does not believe significant credit risk exists in its recorded accounts receivable as of March 31, 2011.

Table of Contents**ARRAY BIOPHARMA, INC.****NOTES TO CONDENSED FINANCIAL STATEMENTS****For the Quarter Ended March 31, 2011****(Unaudited)****NOTE 3 - MARKETABLE SECURITIES**

Marketable securities consisted of the following as of March 31, 2011 (dollars in thousands):

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Short-term available-for-sale securities:				
U.S. Government agency securities	37,542	3	-	37,545
Mutual fund securities	409	-	-	409
Sub-total	37,951	3	-	37,954
Long-term available-for-sale securities:				
Mutual fund securities	527	-	-	527
Sub-total	527	-	-	527
Total	\$ 38,478	\$ 3	\$ -	\$ 38,481

Marketable securities consisted of the following as of June 30, 2010 (dollars in thousands):

	Amortized Cost	Gross Unrealized Gains	Gross Unrealized Losses	Fair Value
Short-term available-for-sale securities:				
U.S. Government agency securities	\$ 78,653	\$ -	\$ (5)	\$ 78,648
Mutual fund securities	16	-	-	16
Sub-total	78,669	-	(5)	78,664

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Long-term available-for-sale securities:						
Auction rate securities		11,027		5,533	-	16,560
Mutual fund securities		799		-	-	799
Sub-total		11,826		5,533	-	17,359
Total	\$	90,495	\$	5,533	(5) \$	96,023

The estimated fair values of these marketable securities were classified into the following fair value measurement categories (dollars in thousands):

		March 31, 2011		June 30, 2010
Quoted prices in active markets for identical assets (Level 1)	\$	38,481	\$	79,463
Significant unobservable inputs (Level 3)		-		16,560
	\$	38,481	\$	96,023

Table of Contents**ARRAY BIOPHARMA, INC.****NOTES TO CONDENSED FINANCIAL STATEMENTS****For the Quarter Ended March 31, 2011****(Unaudited)**

The amortized cost and estimated fair value of available-for-sale securities by contractual maturity as of March 31, 2011 was as follows (dollars in thousands):

	Amortized Cost	Fair Value
Due in one year or less	\$ 37,951	\$ 37,954
Due in one year to three years	527	527
	\$ 38,478	\$ 38,481

Auction Rate Securities

As of June 30, 2010, the Company held five ARS with a par value of \$26.3 million, a cost basis of \$11.0 million and an estimated fair value of \$16.6 million. All of these securities have been sold as of March 31, 2011.

Prior to the disposition of the ARS, and beginning in fiscal 2008, the auctions for all of the Company's ARS were unsuccessful and the Company was unable to readily liquidate its ARS. The lack of successful auctions resulted in the interest rate on these investments increasing to LIBOR plus additional basis points as stipulated in the auction rate agreements, ranging from 200 to 350 additional basis points, which continued from the time the auctions failed through their disposition in the current quarter.

The Company's ARS were measured using Level III, or unobservable inputs, as there was no active market for the securities. The most significant unobservable inputs used in this method were the estimates of the amount of time until a liquidity event will occur and the discount rate, which incorporates estimates of credit risk and a liquidity premium (discount). Due to the inherent complexity in valuing these securities, the Company engaged a third-party valuation firm to perform an independent valuation of the ARS as part of its overall fair value analysis.

Based on its fair value analysis and fair value estimates as of each quarter end, the Company recorded adjustments related to its ARS that are summarized below (dollars in thousands):

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2011	2010	2011	2010
Unrealized gains	\$ -	\$ 1,210	\$ 746	\$ 3,614
Unrealized losses	\$ (3,215)	\$ -	\$ (3,573)	\$ -
Impairment losses	\$ -	\$ -	\$ -	\$ (217)
Net unrealized gains reclassified from equity to earnings upon sale	1,093	524	2,706	915
Additional gains (losses) incurred upon sale, net	-	(167)	(815)	606
Realized gains on auction rate securities, net	\$ 1,093	\$ 357	\$ 1,891	\$ 1,304

Table of Contents

ARRAY BIOPHARMA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
For the Quarter Ended March 31, 2011
(Unaudited)

A rollforward of adjustments to the fair value of the ARS follows (dollars in thousands):

	Nine Months Ended March 31,	
	2011	2010
Balance as of prior year end	\$ 16,560	\$ 16,518
Unrealized gains	746	3,614
Unrealized losses	(3,573)	-
Sale of ARS at sale price	(12,918)	(3,560)
Impairment losses	-	(217)
Additional gains (losses) incurred upon sale, net	(815)	606
Balance as of current quarter end	\$ -	\$ 16,961

NOTE 4 DEFERRED REVENUE

Deferred revenue consisted of the following (dollars in thousands):

	March 31, 2011	June 30, 2010
Amgen, Inc.	\$ 35,598	\$ 50,595
Novartis International Pharmaceutical Ltd.	41,975	42,781
Celgene Corporation	19,474	20,492
Genentech, Inc.	2,063	3,783
Total deferred revenue	99,110	117,651
Less: Current portion	(51,566)	(52,474)
Deferred revenue, long term	\$ 47,544	\$ 65,177

Amgen Inc.

In December 2009, the Company granted Amgen the exclusive worldwide right to develop and commercialize the Company's small molecule glucokinase activator, AMG 151/ARRY-403. Under the Collaboration and License Agreement, the Company is

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

responsible for completing Phase 1 clinical trials on AMG 151. The Company will also conduct further research funded by Amgen to create second generation glucokinase activators. Amgen is responsible for further development and commercialization of AMG 151 and any resulting second generation compounds. The agreement also provides the Company with an option to co-promote any approved drugs with Amgen in the U.S. with certain limitations.

In partial consideration for the rights granted to Amgen under the agreement, Amgen paid the Company an up-front fee of \$60 million in December 2009. Amgen will also pay the Company for research on second generation compounds based on the number of full-time-equivalent scientists working on the discovery program.

The Company is also entitled to receive up to approximately \$666 million in aggregate milestone payments if all clinical and commercialization milestones specified in the agreement for AMG 151 and at least one backup compound are achieved. The Company will also receive royalties on sales of any approved drugs developed under the agreement.

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

The Company estimates that its obligations under the agreement will continue until December 31, 2012 and, therefore, is recognizing the up-front fee on a straight-line basis from the date the agreement was signed on December 13, 2009 through that time in License and Milestone Revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss. The Company recognized \$4.9 million of revenue under the agreement for the three months ended March 31, 2011 and 2010. The Company recognized \$14.8 million and \$5.8 million of revenue under the agreement for the nine months ended March 31, 2011 and 2010, respectively.

The Company records revenue for research performed by its scientists working on the discovery program in Collaboration Revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss. The Company recognized \$1.2 million and \$3.6 million of revenue under the agreement for the three months and nine months ended March 31, 2011, respectively. The Company recognized \$902 thousand of revenue for each of the three and nine months ended March 31, 2010.

The Company is reimbursed for certain development activities, which is recorded in Collaboration Revenue and Cost of Sales in the accompanying Condensed Statements of Operations and Comprehensive Loss. The Company recognized \$556 thousand of Collaboration Revenue and Cost of Sales for the three months ended March 31, 2010. During the nine months ended March 31, 2011 and 2010, the Company recognized Collaboration Revenue and Cost of Sales of \$1.4 million and \$556 thousand, respectively.

Either party may terminate the agreement in the event of a material breach of a material obligation under the agreement by the other party upon 90 days prior notice and Amgen may terminate the agreement at any time upon notice of 60 or 90 days depending on the development activities going on at the time of such notice. The parties have also agreed to indemnify each other for certain liabilities arising under the agreement.

Novartis International Pharmaceutical Ltd.

The Company and Novartis International Pharmaceutical Ltd. entered into a License Agreement in April 2010 granting Novartis the exclusive worldwide right to co-develop and commercialize MEK162/ARRY-162, as well as other specified MEK inhibitors. Under the agreement, the Company is responsible for completing the on-going Phase 1b expansion trial of MEK162 in patients with KRAS or BRAF mutant colorectal cancer and for the further development of MEK162 for up to two indications. Novartis is responsible for all other development activities and for the commercialization of products under the agreement, subject to the Company's option to co-detail approved drugs in the U.S.

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

In consideration for the rights granted to Novartis under the agreement, the Company received \$45 million, comprising an up-front and milestone payment, in the fourth quarter of fiscal 2010, and is also entitled to receive up to approximately \$422 million in aggregate milestone payments if all clinical, regulatory and commercial milestones specified in the agreement are achieved. In March 2011, the Company earned a \$10 million milestone payment, which it will receive in the fourth quarter of fiscal 2011. Novartis will also pay the Company royalties on worldwide sales of any approved drugs, with royalties on U.S. sales at a significantly higher level, assuming the Company continues to co-develop as described below.

The Company estimates that its obligations under the agreement will continue until April 2014 and, therefore, is recognizing the up-front fee and milestone payments on a straight-line basis from the date the agreement was signed in April 2010 through that time.

The Company recognized \$2.5 million and \$7.5 million in revenue related to the up-front payment during the three and nine months ended March 31, 2011, respectively. The Company recognized \$2.7 million and \$3.3 million in revenue related to the two milestone payments during the three and nine months ended March 31, 2011, of which \$2.4 million was attributable to the second milestone. These amounts

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

are recorded in License and Milestone Revenue in the accompanying Condensed Statements of Operations and Comprehensive Loss.

The Novartis agreement also contains co-development rights whereby the Company can elect to pay a percentage share of the combined total development costs. During the first two years of the co-development period, Novartis will reimburse the Company for 100% of the Company's development costs. Beginning in year three, the Company will begin paying its percentage share of the combined development costs since inception of the program, up to a maximum amount with annual caps, unless it opts out of paying its percentage share of these costs. If the Company opts out of paying its share of combined development costs with respect to one or more products, the U.S. royalty rate would then be reduced for any such product based on a specified formula, subject to a minimum that equals the royalty rate on sales outside the U.S., and the Company would no longer have the right to develop or detail such product.

The Company is recording a receivable in the accompanying Condensed Balance Sheets for the amounts due from Novartis for the reimbursement of the Company's development costs. The Company is accruing its percentage share of the combined development costs in the accompanying Condensed Balance Sheets as an Other Long-term Liability, on the basis of the Company's intention to begin paying such amounts to Novartis beginning in year three of the co-development period.

The Company incurred reimbursable development costs of \$1.4 million and \$5.3 million during the three and nine months ended March 31, 2011, respectively which is recorded as a reduction of Cost of Sales in the accompanying Condensed Statements of Operations and Comprehensive Loss, and has recorded a corresponding receivable of \$1.4 million in Prepaid and Other Current Assets in the accompanying Condensed Balance Sheets. The Company's share of the combined development costs was \$1.0 million and \$2.6 million during the three and nine months ended March 31, 2011, respectively, which is recorded in Cost of Sales in the accompanying Condensed Statements of Operations and Comprehensive Loss. Additionally, the Company has recorded a corresponding payable of \$2.6 million in Other Long-Term Liabilities in the accompanying Condensed Balance Sheets.

The agreement will be in effect on a product-by-product and county-by-country basis until no further payments are due with respect to the applicable product in the applicable country, unless terminated earlier. Either party may terminate the agreement in the event of an uncured material breach of a material obligation under the agreement by the other party upon 90 days prior notice. Novartis may terminate portions of the agreement following a change in control of the Company and may terminate the agreement in its entirety or on a product-by-product basis with 180 days prior notice. The Company and Novartis have each further agreed to indemnify the other party for manufacturing or commercialization activities conducted by it under the agreement, negligence or willful misconduct or breach of covenants, warranties or representations made by it under the agreement.

Celgene Corporation

In September 2007, the Company entered into a worldwide strategic collaboration with Celgene focused on the discovery, development and commercialization of novel therapeutics in cancer and inflammation. Under the agreement, Celgene made an up-front payment of \$40 million to the Company to provide research funding for activities conducted by the Company. The Company is responsible for all discovery development through Phase 1 or Phase 2a. Celgene has an option to select a limited number of drugs developed under the collaboration that are directed to up to two of four mutually selected discovery targets and will receive exclusive worldwide rights to the drugs, except for limited co-promotional rights in the U.S. The Company retains all rights to the programs for which Celgene does not exercise its option.

In June 2009, the parties amended the agreement to substitute a new discovery target in place of an existing target and Celgene paid the Company \$4.5 million in consideration for the amendment. No other terms of the agreement with Celgene were modified by the amendment. The option term of this target will expire on or before June 2016, and the option term for the other targets will expire on the earlier of

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

completion of Phase 1 or Phase 2a trials for the applicable drug or September 2014. In September 2009, Celgene notified the Company it was waiving its rights to one of the discovery targets under the collaboration, leaving it the option to select two of the remaining three targets.

The Company is entitled to receive, for each drug for which Celgene exercises an option, potential milestone payments of \$200 million, if certain discovery, development and regulatory milestones are achieved and an additional \$300 million if certain commercial milestones are achieved. In November 2010, the Company earned and subsequently received a \$10 million milestone payment upon securing an Investigational New Drug application for one of the programs. The Company is also entitled to receive royalties on net sales of any drugs.

Upon execution of the agreement, the Company estimated that its discovery obligations under the agreement would continue through September 2014 and accordingly was recognizing as revenue the up-front fees received from the date of receipt through September 2014. Effective October 1, 2009, the Company estimated that its discovery efforts under the agreement will conclude by September 2011. Therefore, the unamortized balance as of December 31, 2009 was amortized on a straight line basis over the shorter period. Effective October 1, 2010, the Company estimated that its discovery efforts under the agreement will conclude by March 2012. Therefore, the unamortized balance as of September 30, 2010 is being amortized on a straight line basis over the longer period.

The Company estimated its development obligations related to the program for which it earned the \$10 million Phase 1 milestone payment in November 2010 would continue through May 2013. Therefore, the Company is recognizing this milestone payment on a straight-line basis from the date it was earned in November 2010 through May 2013.

The Company recognized \$3.7 million and \$4.1 million in revenue related to the up-front and milestone payments during the three months ended March 31, 2011 and 2010, respectively. The Company recognized \$11 million and \$9.8 million related to the up-front and milestone payments during the nine months ended March 31, 2011 and 2010, respectively.

As discussed above, the Company granted Celgene Corporation an option to select up to two of four programs developed under its collaboration agreement and concluded that Celgene was likely to continue funding with respect to two of the four programs by paying the Phase 1 milestone. Accordingly, upon execution of the agreement, the Company began reporting costs associated with the Celgene collaboration as follows: 50% to Cost of Revenue, with the remaining 50% to Research and Development for Proprietary Programs. Celgene waived its rights with respect to one of the programs during the second quarter of fiscal 2010, at which time management determined that Celgene is likely to continue funding one of the remaining three programs and pay the Phase 1 milestone. Accordingly, beginning October 1, 2009, the Company began reporting costs associated with the Celgene

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

collaboration as follows: 33.3% to Cost of Revenue, with the remaining 66.7% to Research and Development for Proprietary Programs. In the second quarter of fiscal 2011, the Company concluded that Celgene is likely to continue funding two of the remaining three programs by paying the Phase 1 milestone. Accordingly, beginning October 1, 2010, the Company began reporting costs associated with the Celgene collaboration as follows: 66.7% to Cost of Revenue, with the remaining 33.3% to Research and Development for Proprietary Programs.

Celgene can terminate any drug development program for which it has not exercised an option at any time, provided that it must give the Company prior notice. In this event, all rights to the program remain with the Company and it would no longer be entitled to receive milestone payments for further development or regulatory milestones that it could have achieved had Celgene continued development of the program. Celgene may terminate the agreement in whole, or in part with respect to individual drug development programs for which Celgene has exercised an option, upon six months written notice to the Company. In addition, either party may terminate the agreement, following certain cure periods, in the event of a breach by the other party of its obligations under the agreement.

Table of Contents**ARRAY BIOPHARMA, INC.****NOTES TO CONDENSED FINANCIAL STATEMENTS**

For the Quarter Ended March 31, 2011

(Unaudited)

NOTE 5 LONG-TERM DEBT

Long-term debt consists of the following (dollars in thousands):

	March 31, 2011	June 30, 2010
Credit Facilities	\$ 126,762	\$ 126,762
Term Loan	15,000	15,000
Long-term debt	141,762	141,762
Less: Unamortized discount on the Credit Facilities	(23,962)	(28,937)
Long-term debt, net	117,800	112,825
Less: Current portion of long-term debt	(150)	-
	\$ 117,650	\$ 112,825

Deerfield Credit Facilities

The Company has entered into two credit facilities (the Credit Facilities) with Deerfield. Under a Facility Agreement entered into with Deerfield in April 2008, the Company borrowed a total of \$80 million (the 2008 Loan), which was funded in two \$40 million payments in June 2008 and December 2008. Terms of the 2008 Credit Facility, including the interest rate and payment terms applicable to the 2008 Loan and covenants relating to minimum cash and cash equivalent balances the Company must maintain, were amended in May 2009 when the Company entered into a new Facility Agreement with Deerfield. Under this Facility Agreement, the Company borrowed \$40 million (the 2009 Loan) on July 31, 2009.

The outstanding principal and any unpaid accrued interest is due on or before April 2014. Interest and principal may be repaid, at the Company's option, at any time with shares of the Company's common stock that have been registered under the Securities Act of 1933, as amended, with certain restrictions, or in cash. The maximum number of shares that the Company can issue to Deerfield under the Credit Facilities without obtaining stockholder approval is 9,622,220 shares.

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Prior to the disbursement of the 2009 Loan, simple interest of 2% annually was paid quarterly and compound interest accrued at an additional 6.5% annually. Upon disbursement of the 2009 Loan, the interest rate on the 2008 Loan was reduced to 7.5% per annum, subject to adjustment as described below, and became payable monthly. Additionally, compound interest stopped accruing on the 2008 Loan.

If the Company's total Cash and Cash Equivalents and Marketable Securities in any month are less than \$60 million, the interest rate under the Facility Agreements is increased to a rate between 8.5% per annum and 14.5% per annum as follows:

Table of Contents**ARRAY BIOPHARMA, INC.****NOTES TO CONDENSED FINANCIAL STATEMENTS****For the Quarter Ended March 31, 2011****(Unaudited)**

Total Cash, Cash Equivalents and Marketable Securities	Applied Interest Rate
\$60 million or greater	7.5%
Between \$50 million and \$60 million	8.5%
Between \$40 million and \$50 million	9.5%
Between \$30 million and \$40 million	12.0%
Less than \$30 million	14.5%

The Credit Facilities contain two embedded derivatives: (1) the variable interest rate structure described above and (2) Deerfield's right to accelerate the loan upon certain changes of control of the Company or an event of default, which is considered a significant transaction contingent put option. As discussed in *Note 1 Overview and Basis of Presentation* under the caption *Long-term Debt and Embedded Derivatives*, these derivatives are valued and reported in Other Long-Term Liabilities in the Company's financial statements and are collectively referred to as the Embedded Derivatives. Under the fair value hierarchy, the Company measured the fair value of the Embedded Derivatives using Level III, or unobservable inputs.

In order to estimate fair value of the variable interest rate feature, the Company makes assumptions as to the interest rates that may be in effect during the term, which in turn depend on the Company's cash and cash equivalent balances. Therefore, the Company must project its monthly cash balances over the term of the Credit Facilities. Such forecasts are inherently subjective and, although management believes the assumptions upon which they are based are reasonable, may not reflect actual results.

In order to estimate the fair value of the put right, the Company estimates the probability of a change in control that would trigger Deerfield's acceleration rights as specified in the Facility Agreements, including a change in control in which the acquirer did not meet certain financial conditions, based on size and credit worthiness. The Company's evaluation of this probability is based on its expectations as to the size and financial strength of probable acquirers, including history of collaboration partners, the probability of an acquisition occurring during the term of the Credit Facilities and other factors, all of which are inherently uncertain and difficult to predict.

Based on these assumptions, the Company estimated the fair value of the Embedded Derivatives to be \$461 thousand and \$825 thousand as of March 31, 2011 and June 30, 2010, respectively.

Management will continue to assess the assumptions used in its determination of the fair value of the Embedded Derivatives, and future changes affecting these assumptions could materially affect their estimated fair value, with a corresponding impact on the Company's reported results of operations. For example, if the Company's projected cash balance was decreased to fall to between

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

\$50 million and \$60 million for approximately twenty months over the remaining life of the loan, compared to two months as currently assumed, in our projected cash balance, then the value of the Embedded Derivatives as of March 31, 2011 would have increased by approximately \$1.3 million.

The Company estimates the fair value of the Deerfield debt using a combination of a discounted cash flow analysis and the Black-Derman-Toy interest rate model that incorporates the estimates discussed above for the Embedded Derivatives. The fair value of the debt was determined to be \$103.7 million and \$95.4 million at March 31, 2011 and June 30, 2010, respectively.

The Company paid Deerfield transaction fees totaling \$2 million when the Company drew the funds under the 2008 Loan, and \$500 thousand on July 10, 2009 and \$500 thousand when the funds were drawn

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

under the 2009 Loan. The transaction fees are included in Other Long-term Assets in the accompanying Condensed Balance Sheets. The Company is amortizing these transaction fees to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss over the respective terms of each of the Credit Facilities. Other direct issuance costs in connection with the transactions were expensed as incurred and were not significant.

The Credit Facilities are secured by a second priority security interest in the Company's assets, including accounts receivable, equipment, inventory, investment property and general intangible assets, excluding copyrights, patents, trademarks, service marks and certain related intangible assets. This security interest and the Company's obligations under the Credit Facilities are subordinate to the Company's obligations to Comerica Bank and to Comerica's security interest, under the Loan and Security Agreement between the Company and Comerica Bank dated June 28, 2005, as amended, discussed below.

The Credit Facility Agreements contain representations, warranties and affirmative and negative covenants that are customary for credit facilities of this type. The Facility Agreements restrict the Company's ability to, among other things, sell certain assets, engage in a merger or change in control transaction, incur debt, pay cash dividends and make investments. The Facility Agreements also contain events of default that are customary for credit facilities of this type, including payment defaults, covenant defaults, insolvency type defaults and events of default relating to liens, judgments, material misrepresentations and the occurrence of certain material adverse events. In addition, if the Company's total Cash, Cash Equivalents and Marketable Securities at the end of a fiscal quarter fall below \$20 million, all amounts outstanding under the Credit Facilities become immediately due and payable. The Company is also required, subject to certain exceptions and conditions, to make payments of principal equal to 15% of certain amounts it receives under collaboration, licensing, partnering, joint venture and other similar arrangements entered into after January 1, 2011.

Warrants Issued to Deerfield

In consideration for providing the 2008 Credit Facility, the Company issued warrants to Deerfield to purchase 6,000,000 shares of Common Stock at an exercise price of \$7.54 per share (the Prior Warrants). Pursuant to the terms of the Facility Agreement for the 2009 Loan, the Prior Warrants were terminated and the Company issued new warrants to Deerfield to purchase 6,000,000 shares of Common Stock at an exercise price of \$3.65 (the Exchange Warrants). The Company also issued Deerfield warrants to purchase an aggregate of 6,000,000 shares of the Company's Common Stock at an exercise price of \$4.19 (the New Warrants and collectively with the Exchange Warrants, the Warrants) when the funds were disbursed on July 31, 2009.

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

The Exchange Warrants contain substantially the same terms as the Prior Warrants, except they have a lower per share exercise price. The Warrants are exercisable commencing January 31, 2010 and expire on April 29, 2014.

On the respective draw down dates of the Credit Facilities, the Company allocated the loan proceeds between the debt and the Warrants based upon their relative estimated fair values. The fair value was allocated to Warrants and Debt Discount in the accompanying Condensed Balance Sheets. All of the discounts attributable to the Warrants are being amortized from the respective draw date of the Credit Facility pursuant to which they were issued to the end of the term of the Credit Facilities.

The Company estimated the fair value of the Warrants using a Black-Scholes option pricing model. The Company calculated the incremental value of the Exchange Warrants as the difference between the value of the Exchange Warrants at the new exercise price (\$3.65) and the value of the Prior Warrants at the prior exercise price (\$7.54) using a Black-Scholes option pricing model.

A summary of the estimated fair value of the Warrants follows (amounts in thousands):

Table of Contents**ARRAY BIOPHARMA, INC.****NOTES TO CONDENSED FINANCIAL STATEMENTS****For the Quarter Ended March 31, 2011****(Unaudited)**

	Proceeds	Warrant Value
2008 Loan	\$ 80,000	\$ 20,589
2009 Loan	\$ 40,000	\$ 12,426
Exchange Warrants	Not Applicable	\$ 3,280

The interest expense recognized by the Company for the Deerfield Credit Facilities follows (dollars in thousands):

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2011	2010	2011	2010
Interest paid	\$ 2,250	\$ 2,250	\$ 6,750	\$ 6,600
Amortization of the transaction fees	140	140	426	408
Amortization of the debt discounts	1,668	1,538	4,976	4,362
Change in value of the Embedded Derivatives	(32)	7	(364)	(199)
Total interest expense on the Deerfield Credit Facility	\$ 4,026	\$ 3,935	\$ 11,788	\$ 11,171

Term Loan and Equipment Line of Credit

The Company entered into a Loan and Security Agreement (Loan and Security Agreement) with Comerica Bank dated June 28, 2005, which has been subsequently amended. The Loan and Security Agreement provides for a term loan, equipment advances and a revolving line of credit, all of which are secured by a first priority security interest in the Company s assets, other than its intellectual property.

The full \$10 million term loan was advanced to the Company on June 30, 2005. The Company received the total \$5 million of equipment advances by June 30, 2007.

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

On September 30, 2009, the term and the interest rate structure of the Loan and Security Agreement were amended. The maturity date was extended 120 days from June 28, 2010 to October 26, 2010. Effective October 1, 2009, the outstanding balances under the term loan and the equipment advances accrued interest on a monthly basis at a rate equal to 2.75% above the Prime Rate, as quoted by Comerica Bank, but not less than the sum of Comerica Bank's daily adjusting LIBOR rate plus 2.5% per annum.

On March 31, 2010, the term and interest rate structure of the Loan and Security Agreement were amended. The term loan and equipment advances were also combined into one instrument referred to as the term loan. The maturity date was extended three years from October 26, 2010 to October 26, 2013. Effective April 1, 2010, the outstanding balances under the term loan and the equipment advances bear interest on a monthly basis at the Prime Rate, as quoted by Comerica Bank, but will not be less than the sum of Comerica Bank's daily adjusting LIBOR rate plus an incremental contractually predetermined rate. This rate is variable, ranging from the Prime Rate to the Prime Rate plus 4%, based on the total dollar amount the Company has invested at Comerica and in what investment option those funds are invested.

In addition, revolving lines of credit of \$6.8 million have been established to support standby letters of credit in relation to the Company's facilities leases. These standby letters of credit expire on January 31, 2014 and August 31, 2016.

As of March 31, 2011, the term loan had an interest rate of 3.25% per annum. The Company recognized \$119 thousand and \$217 thousand of interest expense for the three months ended March 31, 2011 and

Table of Contents

ARRAY BIOPHARMA, INC.
NOTES TO CONDENSED FINANCIAL STATEMENTS
For the Quarter Ended March 31, 2011
(Unaudited)

2010, respectively. The Company recognized \$371 thousand and \$514 thousand of interest expense for the nine months ended March 31, 2011 and 2010, respectively.

The following table outlines the level of Cash, Cash Equivalents and Marketable Securities, which the Company must hold in accounts at Comerica Bank per the Loan and Security Agreement based on the Company's total Cash, Cash Equivalent and Marketable Securities, which was modified as part of the March 31, 2010 amendment.

Total Cash, Cash Equivalents and Marketable Securities	Cash on Hand at Comerica
Greater than \$40 million	\$ -
Between \$25 million and \$40 million	\$ 10,000,000
Less than \$25 million	\$ 22,000,000

The Loan and Security Agreement contains representations and warranties and affirmative and negative covenants that are customary for credit facilities of this type. The Loan and Security Agreement restricts the Company's ability to, among other things, sell certain assets, engage in a merger or change in control transaction, incur debt, pay cash dividends and make investments. The Loan and Security Agreement also contains events of default that are customary for credit facilities of this type, including payment defaults, covenant defaults, insolvency type defaults and events of default relating to liens, judgments, material misrepresentations and the occurrence of certain material adverse events.

The estimated fair value of the Loan and Security Agreement was determined using a discounted cash flow model and was calculated at \$15 million as of March 31, 2011 and June 30, 2010.

Commitment Schedule

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

The Company is required to make principal payments under the Credit Facilities and the Term Loan as follows (dollars in thousands):

For the twelve months ended March 31.

2012	\$	150
2013		150
2014		14,700
2015		126,762
2016		-
	\$	141,762

Table of Contents

ARRAY BIOPHARMA, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

For the Quarter Ended March 31, 2011

(Unaudited)

NOTE 6 SHARE BASED COMPENSATION EXPENSE

All share-based payments to employees are recognized in the Condensed Statements of Operations and Comprehensive Loss based on the fair value of the award on the grant date. Share-based compensation arrangements include stock option grants under the Option Plan and purchases of common stock at a discount under the ESPP. The fair value of all stock options granted by the Company is estimated on the date of grant using the Black-Scholes option pricing model. The Company recognizes share-based compensation expense on a straight-line basis over the vesting term of stock option grants. See *Note 12 - Employee Compensation Plans* to the Company's audited financial statements included in its Annual Report on Form 10-K for the year ended June 30, 2010 for more information about the assumptions used by the Company under this valuation methodology. During the three and nine months ended March 31, 2011 and 2010, the Company made no material changes to these assumptions.

During the three months ended March 31, 2011 and 2010, the Company issued new stock options to purchase a total of 1.1 million shares and 939 thousand shares of common stock, respectively. The Company recognized compensation expense for stock options of \$640 thousand and \$1.0 million for the three months ended March 31, 2011 and 2010, respectively. During the nine months ended March 31, 2011 and 2010, the Company issued new stock options to purchase a total of 1.3 million shares and 1.2 million shares of common stock, respectively. The Company recognized compensation expense for stock options of \$2.3 million and \$3.6 million for the nine months ended March 31, 2011 and 2010, respectively.

As of March 31, 2011, there was \$4.7 million of unrecognized compensation expense, including the impact of expected forfeitures, for unvested share-based compensation awards granted under the Company's equity plans, which the Company expects to recognize over a weighted-average period of 2.5 years.

The fair value of common stock purchased under the ESPP is based on the estimated fair value of the common stock during the offering period and the percentage of the purchase discount. During the three months ended March 31, 2011 and 2010, the Company recognized compensation expense for its ESPP of \$129 thousand and \$178 thousand, respectively. During the nine months ended March 31, 2011 and 2010, the Company recognized compensation expense for its ESPP of \$472 thousand and \$608 thousand, respectively.

Table of Contents**ARRAY BIOPHARMA, INC.****NOTES TO CONDENSED FINANCIAL STATEMENTS****For the Quarter Ended March 31, 2011****(Unaudited)****NOTE 7 EQUITY DISTRIBUTION AGREEMENT**

On September 18, 2009, the Company entered into an Equity Distribution Agreement with Piper Jaffray & Co. (the Agent) pursuant to which the Company may sell from time to time, up to an aggregate of \$25 million in shares of its \$.001 par value common stock, through the Agent that have been registered on a registration statement on Form S-3 (File No. 333-15801). Sales of the shares made pursuant to the Equity Distribution Agreement are made on the NASDAQ Stock Market by means of ordinary brokers transactions at market prices. Additionally, under the terms of the Equity Distribution Agreement, the Company may sell shares of its common stock through the Agent, on the NASDAQ Global Market or otherwise, at negotiated prices or at prices related to the prevailing market price.

A summary of the transaction data follows:

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2011	2010	2011	2010
Number of shares sold	524,184	544,126	1,444,677	1,300,816
Average price per share	\$ 3.06	\$ 2.60	\$ 3.19	\$ 2.72
Gross proceeds (in thousands)	\$ 1,603	\$ 1,415	\$ 4,610	\$ 3,536
Commissions (in thousands)	\$ (48)	\$ (42)	\$ (138)	\$ (106)
Other costs (in thousands)	\$ (27)	\$ (21)	\$ (86)	\$ (264)

NOTE 8 EMPLOYEE BONUS

The Company's annual employee bonus program is payable in cash or in shares of common stock if the Company meets certain financial, discovery, development and partnering goals during a fiscal year. The bonus is typically paid in the second quarter of the next fiscal year, and the Company accrues an estimate of the expected aggregate bonus in Accrued Compensation and Benefits in the accompanying Condensed Balance Sheets. As of March 31, 2011 and June 30, 2010, the Company had \$3.3 million and \$6.5

million accrued in Accrued Compensation and Benefits for the fiscal 2011 and fiscal 2010 bonus programs, respectively.

NOTE 9 SUBSEQUENT EVENT

On May 2, 2011, the Company entered into agreements to modify its Credit Facilities with Deerfield and to issue \$30 million of its Series B Preferred Stock (Preferred Stock) to entities affiliated with Deerfield. The proceeds of the sale of the Preferred Stock will be applied to reduce the total principal due under the Credit Facilities from \$120 million to \$90 million, with approximately \$7 million of previously accrued interest remaining outstanding.

The term of the Credit Facilities will be extended from April 2014 to June 2015 and June 2016, respectively and the principal and accrued interest will be re-paid as follows:

1. Remitting 15% of up-front and milestone payments that the Company receives from new partnering deals through June 2016
2. The remaining balance, less \$20 million, will be repaid June 2015
3. The remaining balance of up to \$20 million will be repaid June 2016

The currently effective annual interest rate remains unchanged at 7.5% of the outstanding principal balance. The accrued interest is non-interest bearing. As part of the modification to the Credit Facilities, the Company also agreed to extend the term of the outstanding warrants owned by Deerfield from April 2014 to June 30, 2016.

The Company will issue 10,135 shares of Series B Preferred Stock at an aggregate price of \$30 million to entities affiliated with Deerfield. The Preferred Stock has a liquidation preference of \$0.001 per share, is non-voting and is convertible into an aggregate of 10,135,000 shares of the Company's Common Stock, provided that conversion will be prohibited if the holder and its affiliates would own more than 9.985% of the total number of the Company's shares of Common Stock then outstanding.

The Company has not yet determined the impact of the accounting treatment for these transactions on its financial statements, however it does expect that there will be a non-cash charge resulting from expensing a portion of the Debt Discount in the fourth quarter of fiscal 2011.

Table of Contents

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our expectations related to the progress and success of drug discovery activities conducted by Array and by our collaborators, our ability to obtain additional capital to fund our operations and/or reduce our research and development spending, realizing new revenue streams and obtaining future out-licensing collaboration agreements that include up-front milestone and/or royalty payments, our ability to realize up-front milestone and royalty payments under our existing or any future agreements, future research and development spending and projections relating to the level of cash we expect to use in operations, our working capital requirements and our future headcount requirements. In some cases, forward-looking statements can be identified by the use of terms such as may, will, expects, intends, plans, anticipates, estimates, potential, or continue, or the negative thereof or other comparable terms. These statements are based on current expectations, projections and assumptions made by management and are not guarantees of future performance. Although we believe that the expectations reflected in the forward-looking statements contained herein are reasonable, these expectations or any of the forward-looking statements could prove to be incorrect and actual results could differ materially from those projected or assumed in the forward-looking statements. Our future financial condition, as well as any forward-looking statements are subject to significant risks and uncertainties, including but not limited to the factors set forth under the heading "Risk Factors" in Item 1A under Part II of this Quarterly Report and under Item 1A of the Annual Report on Form 10-K for the fiscal year ended June 30, 2010 we filed with the Securities and Exchange Commission on August 12, 2010. All forward looking statements are made as of the date hereof and, unless required by law, we undertake no obligation to update any forward-looking statements.

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and notes to those statements included elsewhere in this quarterly report. The terms we, us, our and similar terms refer to Array BioPharma Inc.

Overview

We are a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and inflammatory diseases. Our proprietary drug development pipeline includes clinical candidates that are designed to regulate therapeutically important target pathways. In addition, leading pharmaceutical and biotechnology companies partner with us to discover and develop drug candidates across a broad range of therapeutic areas.

Table of Contents

The most advanced programs currently in clinical trials that we are developing internally or with a partner are as follows:

Program	Target and Indication	Ownership	Clinical Status
1. MEK162 (ARRY-162)	MEK inhibitor for cancer	Array/Novartis	Phase 2
2. ARRY-520	KSP inhibitor for multiple myeloma or MM	Array	Phase 2
3. ARRY-380	HER2 inhibitor for breast cancer	Array	Phase 1
4. ARRY-543	HER2/EGFR inhibitor for cancer	Array	Phase 1b
5. ARRY-614	p38/Tie2 dual inhibitor for myelodysplastic syndrome or MDS	Array	Phase 1
6. ARRY-382	cFMS inhibitor for cancer	Array/Celgene option	Phase 1

In addition to these development programs, our most advanced drugs under development exclusively by a partner are as follows:

Program	Target and Indication	Ownership	Clinical Status
1. Selumetinib (AZD6244)	MEK inhibitor for cancer	Array/AstraZeneca	Phase 2
2. AMG 151 (ARRY-403)	Glucokinase activator for Type 2 diabetes	Array/Amgen	Phase 1
3. Danoprevir (RG7227)	Protease inhibitor for Hepatitis C virus	Array/Roche	Phase 2
4. GDC-0068	AKT inhibitor for cancer	Array/Genentech	Phase 1
5. VTX-2337	Toll-like receptor for cancer	Array/VentiRx	Phase 1/2
6. VTX-1463	Toll-like receptor for allergy	Array/VentiRx	Phase 1b
7. LY2603618	Chk-1 inhibitor for cancer	Array/Eli Lilly	Phase 2

Any information we report about the development plans or the progress or results of clinical trials or other development activities of our partners is based on information that has been reported to us or is otherwise publicly disclosed by our partners.

Our internal discovery efforts have also generated additional early-stage drug candidates, and we may choose to out-license select promising candidates through research partnerships prior to filing an Investigational New Drug, or IND application. We also have a portfolio of proprietary and partnered drug discovery programs that we believe will generate additional IND, applications. We have active, partnered programs with Amgen, Celgene, Genentech and Novartis in which we may earn milestone payments and royalties.

We have built our clinical and discovery programs through spending \$444.8 million from our inception through March 31, 2011. During the first three and nine months of fiscal 2011 we spent \$15.9 million and \$44.2 million in research and development for proprietary programs, respectively. In fiscal 2010, we spent \$72.5 million in research and development for proprietary programs, compared to \$89.6 million and \$90.3 million for fiscal years 2009 and 2008, respectively. During fiscal 2010, we signed strategic

Table of Contents

collaborations with Novartis and Amgen. Together these collaborations provided Array with \$105 million in initial payments, over \$1 billion in potential milestone payments if all clinical and commercialization milestones under the agreements are achieved, potential double digit royalties and potential commercial co-detailing rights.

We have received a total of \$507.1 million in research funding and in up-front and milestone payments from our collaboration partners since inception through March 31, 2011. Under our existing collaboration agreements, we have the potential to earn over \$2.8 billion in additional milestone payments if we or our collaborators achieve all the drug discovery, development and commercialization objectives detailed in those agreements, as well as the potential to earn royalties on any resulting product sales from 17 drug development programs.

Our significant collaborators include:

- Amgen, which entered into a worldwide strategic collaboration with us to develop and commercialize our glucokinase activator, AMG 151.
- AstraZeneca, which licensed three of our MEK inhibitors for cancer, including Selumetinib, which is currently in multiple Phase 2 clinical trials.
- Celgene Corporation, which entered into a worldwide strategic collaboration agreement with us focused on the discovery, development and commercialization of novel therapeutics in cancer and inflammation.
- Genentech, which entered into a worldwide strategic collaboration agreement with us focused on the discovery of novel therapeutics. One drug, GDC-0068, an AKT inhibitor for cancer, entered a Phase 1 trial during the first half of 2010. The other programs are in discovery or preclinical development.
- Novartis, which entered into a worldwide strategic collaboration with us to develop and commercialize our MEK inhibitor, MEK162, which is currently in Phase 2 clinical trials.
- Roche Holding AG, which acquired Danoprevir, a novel small molecule inhibitor of the Hepatitis C Virus NS3/4 protease from InterMune, which we had invented in collaboration with InterMune. Danoprevir is currently in Phase 2b clinical trials.

Fiscal Periods

Our fiscal year ends on June 30. When we refer to a fiscal year or quarter, we are referring to the year in which the fiscal year ends and the quarters during that fiscal year. Therefore, fiscal 2011 refers to the fiscal year ending June 30, 2011 and the third quarter refers to the quarter ended March 31, 2011.

Business Development and Collaborator Concentrations

We license or partner certain of our compounds and/or programs and enter into collaborations directly with pharmaceutical and biotechnology companies through opportunities identified by our business development group, senior management, scientists and referrals.

Table of Contents

The following collaborators contributed greater than 10% of our total revenue for the periods presented:

	Three Months Ended			Nine Months Ended		
	March 31,			March 31,		
	2011		2010	2011		2010
Amgen, Inc.	34%		35%	37%		20%
Novartis International Pharmaceutical Ltd.	30%		-	22%		-
Celgene Corporation	21%		23%	21%		28%
Genentech, Inc.	14%		42%	20%		48%
	99%		100%	100%		96%

In general, certain of our collaborators may terminate their collaboration agreements with 90 to 180 days prior notice. Our agreement with Genentech can be terminated with 120 days notice. Celgene may terminate its agreement with us with six months notice. Amgen may terminate its agreement with us at any time upon notice of 60 or 90 days depending on the development activities going on at the time of such notice.

The following table details revenue from our collaborators by region based on the country in which collaborators are located or the ship-to destination for compounds (dollars in thousands):

	Three Months Ended			Nine Months Ended				
	March 31,			March 31,				
	2011		2010	2011		2010		
North America	\$	12,456	\$	18,310	\$	41,285	\$	35,706
Europe		5,381		52		11,555		161
Asia Pacific		4		14		15		43
	\$	17,841	\$	18,376	\$	52,855	\$	35,910

All of our collaboration agreements are denominated in U.S. dollars.

Critical Accounting Policies and Estimates

Management's discussion and analysis of financial condition and results of operations are based upon our accompanying Condensed Financial Statements, which have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses as well as the disclosure of contingent assets and liabilities. We regularly review our estimates and assumptions.

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

These estimates and assumptions, which are based upon historical experience and on various other factors believed to be reasonable under the circumstances, form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Reported amounts and disclosures may have been different had management used different estimates and assumptions or if different conditions had occurred in the periods presented.

Below is a discussion of the policies and estimates that we believe involve a high degree of judgment and complexity.

Table of Contents

Revenue Recognition

Most of our revenue is from our collaborators for research funding, up-front or license fees and milestone payments derived from discovering and developing drug candidates. Our agreements with collaboration partners include fees based on annual rates for full-time-equivalent employees (FTEs) working on a program and may also include non-refundable license and up-front fees, non-refundable milestone payments that are triggered upon achievement of specific research or development goals and future royalties on sales of products that result from the collaboration. A small portion of our revenue comes from the sale of compounds on a per-compound basis. We report FTE fees for discovery and the development of proprietary drug candidates that we out-license as Collaboration Revenue. License and Milestone Revenue is combined and consists of up-front fees and ongoing milestone payments from collaborators that are recognized during the applicable period.

We recognize revenue in accordance with Staff Accounting Bulletin No. 104, *Revenue Recognition* (SAB 104), which establishes four criteria, each of which must be met, in order to recognize revenue for the performance of services or the shipment of products. Revenue is recognized when (a) persuasive evidence of an arrangement exists, (b) products are delivered or services are rendered, (c) the sales price is fixed or determinable and (d) collectability is reasonably assured.

Collaboration agreements that include a combination of discovery research funding, up-front or license fees, milestone payments and/or royalties are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet the separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting in accordance with SAB 104.

We recognize revenue from non-refundable up-front payments and license fees on a straight-line basis over the term of performance under the agreement, which is generally the estimated research or development term. These advance payments are deferred and recorded as Deferred Revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying Condensed Balance Sheets.

When the performance period is not specifically identifiable from the agreement, we estimate the performance period based upon provisions contained within the agreement, such as the duration of the research or development term, the existence, or likelihood of achievement of development commitments and any other significant commitments of ours.

Most of our agreements provide for milestone payments. In certain cases, a portion of each milestone payment is recognized as revenue when the specific milestone is achieved based on the applicable percentage of the estimated research or development term that has elapsed to the total estimated research and/or development term. In other cases, when the milestone payment is attributed to future development obligations of Array, the revenue is recognized on a straight-line basis over the estimated remaining development period. Certain milestone payments are for activities for which there are no future obligations and as a result, are recognized when earned in their entirety.

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

We periodically review the expected performance periods under each of our agreements that provide for non-refundable up-front payments and license fees and milestone payments and adjust the amortization periods when appropriate to reflect changes in assumptions relating to the duration of expected performance periods. Revenue recognition for non-refundable license fees and up-front payments and milestone payments could be accelerated in the event of early termination of programs or alternatively, decelerated, if programs are extended. As such, while changes to such estimates have no impact on our reported cash flows, our reported revenue is significantly influenced by our estimates of the period over which our obligations are expected to be performed.

Table of Contents

Cost of Revenue and Research and Development for Proprietary Programs

We incur costs in connection with performing research and development activities which consist mainly of compensation, associated fringe benefits, share-based compensation, preclinical and clinical outsourcing costs and other collaboration-related costs, including supplies, small tools, facilities, depreciation, recruiting and relocation costs and other direct and indirect chemical handling and laboratory support costs. We allocate these costs between Cost of Revenue and Research and Development for Proprietary Programs based upon the respective time spent by our scientists on development conducted for our collaborators and for our internal proprietary programs. Cost of Revenue represents the costs associated with research and development, including preclinical and clinical trials, conducted by us for our collaborators. Research and Development for Proprietary Programs consists of direct and indirect costs for our specific proprietary programs. We do not bear any risk of failure for performing these activities and the payments are not contingent on the success or failure of the research program. Accordingly, we expense these costs when incurred.

Where our collaboration agreements provide for us to conduct research and development and for which our partner has an option to obtain the right to conduct further development and to commercialize a product, we attribute a portion of its research and development costs to Cost of Revenue based on the percentage of total programs under the agreement that we conclude is likely to continue to be funded by the partner. These costs may not be incurred equally across all programs. In addition, we continually evaluate the progress of development activities under these agreements and if events or circumstances change in future periods that we reasonably believe would make it unlikely that a collaborator would continue to fund the same percentage of programs, we will adjust the allocation accordingly. See *Note 4 Deferred Revenue*, for further information about our collaborations.

Accrued Outsourcing Costs

Substantial portions of our preclinical studies and clinical trials are performed by third-party laboratories, medical centers, contract research organizations and other vendors (collectively CROs). These CROs generally bill monthly or quarterly for services performed or bill based upon milestone achievement. For preclinical studies, we accrue expenses based upon estimated percentage of work completed and the contract milestones remaining. For clinical studies, expenses are accrued based upon the number of patients enrolled and the duration of the study. We monitor patient enrollment, the progress of clinical studies and related activities to the extent possible through internal reviews of data reported to us by the CROs, correspondence with the CROs and clinical site visits. Our estimates depend on the timeliness and accuracy of the data provided by the CROs regarding the status of each program and total program spending. We periodically evaluate our estimates to determine if adjustments are necessary or appropriate based on information we receive.

Marketable Securities

We have designated our marketable securities as of each balance sheet date as available-for-sale securities and account for them at their respective fair values. Marketable securities are classified as short-term or long-term based on the nature of these securities and the availability of these securities to meet current operating requirements. Marketable securities that are readily available for use in current operations are classified as short-term available-for-sale securities and are reported as a component of current assets in the accompanying Condensed Balance Sheets. Marketable securities that are not considered available for use in current operations (including when active markets for such securities do not exist) are classified as long-term available-for-sale securities and are reported as a component of long-term assets in the accompanying Condensed Balance Sheets.

Securities that are classified as available-for-sale are carried at fair value, including accrued interest, with temporary unrealized gains and losses reported as a component of Stockholders' Deficit until their disposition. We review all available-for-sale securities each period to determine if they remain available-for-sale based on our then current intent and ability to sell the security if we are required to do so. The

Table of Contents

amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in Interest Income in the accompanying Condensed Statements of Operations and Comprehensive Loss. Realized gains and losses on ARS along with declines in value judged to be other-than-temporary are reported in Realized Gains on Auction Rate Securities, Net in the accompanying Condensed Statements of Operations and Comprehensive Loss when recognized. The cost of securities sold is based on the specific identification method.

We sold our remaining ARS during the quarter ended March 31, 2011. Prior to their disposition, we measured the ARS under the fair value hierarchy, described below under Fair Value Measurements, using Level III, or unobservable inputs, as there was no active market for the securities. The most significant unobservable inputs used in this method are estimates of the amount of time until a liquidity event will occur and the discount rate, which incorporates estimates of credit risk and a liquidity premium (discount). Due to the inherent complexity in valuing these securities, we engaged a third-party valuation firm to perform an independent valuation of the ARS as part of our overall fair value analysis beginning with the first quarter of fiscal 2009 and continuing through the quarter ended December 31, 2010.

See Note 3 *Marketable Securities* for additional information about our investments in ARS.

Fair Value Measurements

Our financial instruments are recognized and measured at fair value in our financial statements and primarily consist of cash and cash equivalents, marketable securities, long-term investments, trade receivables and payables, long-term debt, embedded derivatives associated with the long-term debt and warrants. We use different valuation techniques to measure the fair value of assets and liabilities, as discussed in more detail below. Fair value is defined as the price that would be received or paid to sell the financial instruments in an orderly transaction between market participants at the measurement date. We use a framework for measuring fair value based on a hierarchy that distinguishes sources of available information used in fair value measurements and categorizes them into three levels:

- Level I: Quoted prices in active markets for identical assets and liabilities.
- Level II: Observable inputs other than quoted prices in active markets for identical assets and liabilities.
- Level III: Unobservable inputs.

We disclose assets and liabilities measured at fair value based on their level in the hierarchy. Considerable judgment is required in interpreting market and other data to develop estimates of fair value for assets or liabilities for which there are no quoted prices in active markets, which include our ARS, warrants issued by us in connection with our long-term debt and the embedded derivatives associated with the long-term debt. The use of different assumptions and/or estimation methodologies may have a material effect on their estimated fair value. Accordingly, the fair value estimates we disclose may not be indicative of the amount that we or holders of the instruments could realize in a current market exchange.

We periodically review the realizability of each investment when impairment indicators exist with respect to the investment. If an other-than-temporary impairment of the value of an investment is deemed to exist, the cost basis of the investment is written down to its then estimated fair value.

Long-term Debt and Embedded Derivatives

The terms of our long-term debt are discussed in detail in *Note 5 Long-term Debt* included elsewhere in this Quarterly Report on Form 10-Q. The accounting for these arrangements is complex and is based upon significant estimates by management. We review all debt agreements to determine the appropriate accounting treatment when the agreement is entered into and review all amendments to determine if the changes require accounting for the amendment as a modification, or as an extinguishment and new debt. We also review each long-term debt arrangement to determine if any feature of the debt requires

Table of Contents

bifurcation and/or separate valuation. These may include hybrid instruments, which are comprised of at least two components ((1) a debt host instrument and (2) one or more conversion features), warrants and other embedded derivatives, such as puts and other rights of the debt holder.

We currently have two embedded derivatives related to our long-term debt with Deerfield that were valued at \$461 thousand and \$825 thousand at March 31, 2011 and June 30, 2010, respectively, and included in Other Long-term Liabilities in the accompanying Condensed Balance Sheets. One of the embedded derivatives is a variable interest rate structure that constitutes a liquidity-linked variable spread feature. The other is a significant transaction contingent put option relating to Deerfield's ability to accelerate the repayment of the debt in the event of certain changes in control of our company. Such event would occur if the acquirer did not meet certain financial conditions, based on size and credit worthiness. Collectively, they are referred to as the Embedded Derivatives. Under the fair value hierarchy, we measure the fair value of the Embedded Derivatives using Level III, or unobservable inputs, as there is no active market for them, and calculate fair value using a combination of a discounted cash flow analysis and the Black-Derman-Toy interest rate model.

The fair value of the variable interest rate structure is based on our estimate of the probable effective interest rate over the term of the Deerfield credit facilities that is based on our cash flow forecasts, which include our expectations of future cash inflows from up-front fees, milestone payments and issuances of equity. The fair value of the put option is based on our estimate of the probability that a change in control that triggers Deerfield's right to accelerate the debt will occur. With those inputs, the fair value of each Embedded Derivative is calculated as the difference between the fair value of the Deerfield credit facilities if the Embedded Derivatives are included and the fair value of the Deerfield credit facilities if the Embedded Derivatives are excluded. Due to the inherent complexity in valuing the Deerfield credit facilities and the Embedded Derivatives, we engaged a third-party valuation firm to perform the valuation as part of our overall fair value analysis. The estimated fair value of the Embedded Derivatives was determined based on management's judgment and assumptions and the use of different assumptions could result in significantly different estimated fair values.

The initial fair value of the Embedded Derivatives was recorded as Derivative Liabilities and as Debt Discount in our Condensed Balance Sheets. Changes in the value of the Embedded Derivatives is adjusted quarterly and recorded to Derivative Liabilities in the Condensed Balance Sheets and Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

Warrants that we have issued in connection with our long-term debt arrangements have been classified as equity. We value the warrants at issuance based on a Black-Scholes option pricing model and then allocate a portion of the proceeds under the debt to the warrants based upon their relative fair values. The warrants are recorded in Stockholders' Equity with the offset to Debt Discount. The Debt Discount is being amortized from the respective draw dates to the end of the term of the Deerfield credit facilities using the effective interest method and recorded as Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss.

Transaction fees paid in connection with our long-term debt arrangements that qualify for capitalization are recorded as Other Long-Term Assets in the Condensed Balance Sheets and amortized to Interest Expense in the accompanying Condensed Statements of Operations and Comprehensive Loss using the effective interest method over the term of the underlying debt agreement.

Table of Contents**Results of Operations*****Collaboration Revenue***

Collaboration Revenue consists of revenue for our performance of drug discovery and development activities in collaboration with partners, which include: co-development of proprietary drug candidates we out-license as well as research, or discovery, that includes screening, lead generation, lead optimization and pharmacological testing (dollars in thousands):

	Three Months Ended March 31,		Change 2011 vs. 2010		Nine Months Ended March 31,		Change 2011 vs. 2010	
	2011	2010	\$	%	2011	2010	\$	%
Collaboration revenue	\$ 3,934	\$ 5,396	\$ (1,462)	-27%	\$ 15,024	\$ 14,874	\$ 150	1%

Collaboration revenue decreased \$1.5 million, or 27%, for the three months ended March 31, 2011 compared to the same period last year. During the current quarter, we recognized \$1.3 million less in revenue on our collaboration with Genentech due to having fewer scientists engaged on the Genentech programs.

Collaboration revenue increased 1% for the nine months ended March 31, 2011 compared to the same period in the prior year. We recognized \$5.0 million during the nine months ended March 31, 2011 from our collaboration with Amgen compared to \$1.5 million in the prior year. This increase was due to the collaboration beginning in December 2010. This was offset by a \$3.7 million decrease in the revenue from our collaboration with Genentech due to fewer scientists engaged on the Genentech programs this year.

License and Milestone Revenue

License and Milestone Revenue are combined and consist of up-front license fees and ongoing milestone payments from collaborators as follows (dollars in thousands):

	Three Months Ended March 31,		Change 2011 vs. 2010		Nine Months Ended March 31,		Change 2011 vs. 2010	
	2011	2010	\$	%	2011	2010	\$	%
License revenue	\$ 10,225	\$ 9,230	995	11%	32,319	16,286	16,033	98%
Milestone revenue	3,682	3,750	(68)	-2%	5,512	4,750	762	16%
Total revenue	\$ 13,907	\$ 12,980	\$ 927	7%	\$ 37,831	\$ 21,036	\$ 16,795	80%

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

License revenue increased \$1.0 million, or 11%, for the three months ended March 31, 2011 compared to the same period last year. During the current quarter, we recognized \$2.5 million of revenue under our collaboration with Novartis that began in April 2010. This was offset by \$1.4 million less revenue recognized under the Celgene collaboration due to our conclusion that the remaining estimated performance period increased by six months effective September 30, 2010 as discussed in *Note 4 Deferred Revenue* to the accompanying Condensed Financial Statements.

License revenue increased \$16 million, or 98%, for the nine months ended March 31, 2011 compared to the prior year due to the incremental revenue for our collaborations with Amgen and Novartis.

Total Milestone Revenue decreased 2% for the three months ended March 31, 2011 compared to the same period last year. In the current quarter, we recognized \$2.7 million from Novartis and \$1 million from Celgene. In the same period of the prior year we recognized \$3.8 million in milestones from Genentech.

Table of Contents

Total Milestone Revenue increased \$762 thousand, or 16%, for the nine months ended March 31, 2011 compared to the same period last year. In the current year, we recognized \$3.3 million from Novartis and \$1.5 million from Celgene. In the same period of the prior year we recognized \$3.8 million in milestones from Genentech and we recognized a \$1 million milestone from our collaboration with InterMune.

Cost of Revenue

Cost of Revenue represents costs for research or discovery and development including preclinical and clinical trials we conduct with or for our collaborators. These costs consist mainly of compensation, associated fringe benefits, share-based compensation, preclinical and clinical outsourcing costs and other collaboration-related costs, including supplies, small tools, travel and meals, facilities, depreciation, recruiting and relocation costs and other direct and indirect chemical handling and laboratory support costs as follows (dollars in thousands):

	Three Months Ended		Change 2011 vs. 2010		Nine Months Ended		Change 2011 vs. 2010	
	2011	2010	\$	%	2011	2010	\$	%
Cost of revenue	\$ 6,617	\$ 7,946	\$ (1,329)	-17%	\$ 21,281	\$ 19,103	\$ 2,178	11%
Cost of revenue as a percentage of total revenue	37%	43%			40%	53%		

Cost of Revenue increased in absolute dollars and decreased as a percentage of total revenue for the nine months ended March 31, 2011 compared to the same period in the prior year. The increase in absolute dollars was for transitioning the underlying program costs for our AMG 151 and MEK162 programs from Research and Development for Proprietary Programs to Cost of Revenue after we partnered these programs with Amgen and Novartis, respectively. Additionally, effective October 1, 2010, we increased the percentage of costs allocated under the Celgene collaboration from 33.3% to Cost of Revenue to 67.7%, as discussed further in *Note 4 Deferred Revenue* to the accompanying Condensed Financial Statements. These increases were partially offset by fewer scientists engaged on our collaboration with Genentech than in the prior fiscal year. During the current quarter, Cost of Revenue decreased in absolute dollars and as a percentage of total revenue. The decrease in absolute dollars was caused by the completion of our obligations to continue to progress AMG 151 through certain Phase 1 clinical trials which were ongoing during the same quarter of the prior fiscal year, as well as fewer FTEs working on the Genentech programs. These decreases were partially offset by the transition of MEK162 to Cost of Sales and the changed allocation of Celgene costs as discussed above.

The decrease of Cost of Revenue as a percentage of total revenue in the three and nine month periods was because of greater License and Milestone Revenue recognized during the periods.

Research and Development for Proprietary Programs

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Research and development expenses include costs associated with our proprietary programs for scientific and clinical personnel, supplies, inventory, equipment, small tools, travel and meals, depreciation, consultants, sponsored research, allocated facility costs, costs for preclinical and clinical trials and share-based compensation. We manage our proprietary programs based on scientific data and achievement of research plan goals. Our scientists record their time to specific projects when possible; however, many activities simultaneously benefit multiple projects and cannot be readily attributed to a specific project. Accordingly, the accurate assignment of time and costs to a specific project is difficult and may not give a true indication of the actual costs of a particular project. As a result, we do not report costs on a program basis but rather on an operational basis as follows (dollars in thousands):

Table of Contents

	Three Months Ended		Change 2011 vs. 2010		Nine Months Ended		Change 2011 vs. 2010	
	2011	2010	\$	%	2011	2010	\$	%
Salaries, benefits and share-based compensation	\$ 7,184	\$ 8,209	\$ (1,025)	-12%	\$ 20,373	\$ 24,088	\$ (3,715)	-15%
Outsourced services and consulting	3,739	4,094	(355)	-9%	9,548	14,818	(5,270)	-36%
Laboratory supplies	2,435	2,642	(207)	-8%	7,028	8,419	(1,391)	-17%
Facilities and depreciation	2,154	2,357	(203)	-9%	6,155	7,524	(1,369)	-18%
Other	371	390	(19)	-5%	1,115	1,148	(33)	-3%
Total research and development for proprietary programs	\$ 15,883	\$ 17,692	\$ (1,809)	-10%	\$ 44,219	\$ 55,997	\$ (11,778)	-21%

Research and Development for Proprietary Programs for the first nine months of fiscal 2011 decreased compared to the prior year because we moved development costs for AMG 151 and MEK162 out of Research and Development for Proprietary Programs to Cost of Revenue as a result of partnering those programs with Amgen and Novartis, respectively. Additionally, effective October 1, 2010, we reduced the allocation of Celgene costs charged to Research and Development for Proprietary Programs as discussed under Cost of Revenue and in *Note 4 Deferred Revenue* to the accompanying Condensed Financial Statements. These decreases were partially offset by increased costs to advance our wholly-owned programs through clinical studies. During the current quarter, Research and Development for Proprietary Programs decreased due to the changes discussed above related to Novartis, Celgene and our wholly-owned programs.

General and Administrative Expenses

General and Administrative Expenses consist mainly of compensation and associated fringe benefits, management, business development, accounting, information technology and administration costs, including patent filing and prosecution, recruiting and relocation, consulting and professional services, travel and meals, sales commissions, facilities, depreciation and other office expenses as follows (dollars in thousands):

	Three Months Ended		Change 2011 vs. 2010		Nine Months Ended		Change 2011 vs. 2010	
	2011	2010	\$	%	2011	2010	\$	%
General and administrative	\$ 3,795	\$ 4,264	\$ (469)	-11%	\$ 11,969	\$ 12,938	\$ (969)	-7%

General and administrative expenses decreased during the three and nine months ended March 31, 2011 compared to the same periods in the prior year. The decreases are the result of lower stock compensation expense from fully vested options as well as a decreased estimated liability for the fiscal 2011 bonus compared to fiscal 2010, and lower business taxes. Professional services for legal and auditing are approximately \$650 thousand less than the same period in the prior year while other consulting fees related to business development and our IT infrastructure have increased approximately \$115 thousand and \$250 thousand during the three and nine month periods, respectively. Additionally, costs to obtain and protect our patents decreased approximately \$180 thousand and increased approximately \$325 thousand during the three and nine month periods ending March 31, 2011, respectively.

Table of Contents**Other Income (Expense)**

A summary of our Other Income (Expense) follows (dollars in thousands):

	Three Months Ended March 31,		Change 2011 vs. 2010		Nine Months Ended March 31,		Change 2011 vs. 2010	
	2011	2010	\$	%	2011	2010	\$	%
Realized gains on auction rate securities, net	\$ 1,093	\$ 357	\$ 736	206%	\$ 1,891	\$ 1,304	\$ 587	45%
Interest income	31	164	(133)	-81%	391	726	(335)	-46%
Interest expense	(4,172)	(4,152)	(20)	0%	(12,240)	(11,685)	(555)	5%
Total other expense, net	\$ (3,048)	\$ (3,631)	\$ 583	-16%	\$ (9,958)	\$ (9,655)	\$ (303)	3%

Components of Interest Expense are as follows (dollars in thousands):

	Three Months Ended March 31,		Nine Months Ended March 31,	
	2011	2010	2011	2010
Credit Facilities:				
Interest paid	\$ 2,250	\$ 2,250	\$ 6,750	\$ 6,600
Amortization of the transaction fees	140	140	426	408
Amortization of the debt discounts	1,668	1,538	4,976	4,362
Change in value of the Embedded Derivatives	(32)	7	(364)	(199)
Total interest expense on Deerfield Credit Facility	4,026	3,935	11,788	11,171
Term Loan:				
Variable interest and amortization of transaction fees	146	217	452	514
Total interest expense on Comerica Loan	146	217	452	514
Total interest expense	\$ 4,172	\$ 4,152	\$ 12,240	\$ 11,685

Liquidity and Capital Resources

We have incurred operating losses and have an accumulated deficit as a result of ongoing research and development spending. As of March 31, 2011, we had an accumulated deficit of \$525.4 million. We had net losses of \$11.5 million and \$34.6 million for the three and nine months ended March 31, 2011, respectively. We had net losses of \$77.6 million, \$127.8 million and \$96.3 million for the fiscal years ended June 30, 2010, 2009 and 2008, respectively.

We have historically funded our operations from up-front fees and license and milestone payments received under our collaboration and out-licensing transactions, from the issuance and sale of equity securities and through debt provided by our credit facilities. For example, we have received \$119.5 million in the last 18 months, including the following payments under our collaborations:

- In December 2009, we received a \$60 million up-front payment from Amgen Inc. under a Collaboration and License Agreement
- In April 2010, we received \$45 million in an up-front and milestone payment under a License Agreement with Novartis Pharmaceutical International Ltd.
- In December 2010, we received \$10 million in a milestone payment under a License Agreement with Celgene Corporation.

The recognition of revenue under these agreements is discussed further in *Note 4 Deferred Revenue*. However, until we can generate sufficient levels of cash from our operations, which we do not expect to achieve in the foreseeable future, we will continue to utilize our existing cash, cash equivalents and marketable securities.

Table of Contents

We use approximately \$20 million per quarter to fund our operations. We believe that the cash, cash equivalents and marketable securities we hold as of March 31, 2011, will enable us to continue to fund our operations for at least the next 12 months assuming we continue to obtain funding through up-front fees from new out-licensing transactions and milestone payments from new and/or existing collaborations. The ability to continue to fund ongoing operations also assumes that we will continue to satisfy our interest payment obligations under the credit facilities with Deerfield with the proceeds from sales of our common stock pursuant to the Equity Distribution Agreement with Piper Jaffray & Co. discussed in Note 8 Equity Distribution Agreement or through the issuance of shares of common stock to Deerfield in accordance with our Facility Agreements with Deerfield. We may also fund operations through the sale of our equity securities. Although we are currently in active licensing discussions with a number of potential partners on select programs, there can be no assurance that we will successfully close new collaborations that provide for up-front fees. Furthermore, sufficient funds may not continue to be available to us when needed from existing or future collaborations or from the proceeds of debt or equity financings.

If we are unable to obtain additional funding from these or other sources when needed or to the extent needed, it may be necessary to significantly reduce our current rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient funds may also require us to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to us or our stockholders than we would otherwise choose in order to obtain up-front license fees needed to fund our operations.

Our ability to realize milestone or royalty payments under existing collaboration agreements and to enter into new partnering arrangements that generate additional revenue through up-front fees and milestone or royalty payments is subject to a number of risks, many of which are beyond our control and include the following:

- The drug development process is risky and highly uncertain and we may not be successful in generating proof-of-concept data to create partnering opportunities and, even if we are, we or our collaborators may not be successful in commercializing drug candidates we create;
- Our collaborators have substantial control and discretion over the timing and continued development and marketing of drug candidates we create and, therefore, we may not receive milestone, royalty or other payments when anticipated or at all;
- The drug candidates we develop may not obtain regulatory approval;
- If regulatory approval is received, drugs we develop will remain subject to regulation or may not gain market acceptance, which could delay or prevent us from generating milestone, royalty revenue or product revenue from the commercialization of these drugs; and
- The spending priorities and willingness of pharmaceutical companies to in-license drugs for further development and commercialization.

Our assessment of our future need for funding is a forward-looking statement that is based on assumptions that may prove to be wrong and that involve substantial risks and uncertainties. Our actual future capital requirements could vary as a result of a number of factors, including:

- Our ability to enter into agreements to out-license, co-develop or commercialize our proprietary drug candidates and the timing of payments under those agreements throughout each candidate's development stage;
- The number and scope of our research and development programs;
- The progress and success of our preclinical and clinical development activities;
- The progress and success of the development efforts of our collaborators;
- Our ability to maintain current collaboration agreements;

- The costs involved in enforcing patent claims and other intellectual property rights;
- The costs and timing of regulatory approvals; and/or

Table of Contents

- The expenses associated with unforeseen litigation, regulatory changes, competition and technological developments, general economic and market conditions and the extent to which we acquire or invest in other businesses, products and technologies.

Cash, Cash Equivalents and Marketable Securities

Cash equivalents are short-term, highly liquid financial instruments that are readily convertible to cash and have maturities of 90 days or less from the date of purchase.

Marketable securities classified as short-term consist primarily of U.S. government agency obligations with maturities of greater than 90 days when purchased. Marketable securities classified as long-term consisted primarily of our investments in ARS as of June 30, 2010. We have sold all of our ARS as of March 31, 2011. See *Note 3 Marketable Securities* in the accompanying Condensed Financial Statements for more information regarding our ARS.

Following is a summary of our cash, cash equivalents and marketable securities (dollars in thousands):

	March 31, 2011	June 30, 2010	\$ Change
Cash and cash equivalents	\$ 37,354	\$ 32,846	\$ 4,508
Marketable securities - short-term	37,954	78,664	(40,710)
Marketable securities - long-term	527	17,359	(16,832)
Total	\$ 75,835	\$ 128,869	\$ (53,034)

Cash Flow Activities

Following is a summary of our cash flows (dollars in thousands):

	Nine Months Ended March 31,		
	2011	2010	\$ Change
Cash flows provided by (used in):			
Operating activities	\$ (52,817)	\$ (3,734)	\$ (49,083)
Investing activities	52,709	9,814	42,895
Financing activities	4,616	43,278	(38,662)
Total	\$ 4,508	\$ 49,358	\$ (44,850)

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Net cash used in operating activities for the nine months ended March 31, 2011 increased \$49 million over the same period in the prior year. This was due to the \$60 million up-front license fee from Amgen in December of 2009 that did not recur. Partially offsetting this was a \$27 million reduction in the net loss in the nine months ended March 31, 2011 compared to the same period in 2010 attributable to higher License and Milestone Revenue and decreased spending on Research and Development for Proprietary Programs.

Net cash provided by investing activities was \$52.7 million and \$9.8 million in the nine months ended March 31, 2011 and 2010, respectively. Prior to the fourth quarter of fiscal 2010, we were not purchasing additional marketable securities upon the maturity of securities we held, and as such, cash flows provided by investing activities was limited.

Table of Contents

Net cash provided by financing activities was \$4.6 million and \$43.3 million in the nine months ended March 31, 2011 and 2010, respectively. The difference between the periods is attributable to the \$39 million in net proceeds we received in the first quarter of fiscal 2010 under the Deerfield credit facilities. During the nine months ended March 31, 2011 and 2010, we also received \$4.4 million and \$3.2 million, respectively, in net proceeds from sales of shares of our common stock under our Equity Distribution Agreement with Piper Jaffray & Co.

Obligations and Commitments

The following table shows our contractual obligations and commitments by maturity as of March 31, 2011 (dollars in thousands):

	Less Than 1 Year	1 to 3 Years	4 to 5 Years	Over 5 Years	Total
Debt obligations (1)	\$ 150	\$ 14,850	\$ 126,762	\$ -	\$ 141,762
Interest on debt obligations (3) (4)	9,483	18,754	750	-	28,987
Operating lease commitments (2)	8,016	16,388	16,479	2,440	43,323
Purchase obligations (2)	15,058	1,905	8	-	16,971
Total	\$ 32,707	\$ 51,897	\$ 143,999	\$ 2,440	\$ 231,043

(1) Reflected in the accompanying Condensed Balance Sheets.

(2) These obligations are not reflected in the accompanying Condensed Balance Sheets.

(3) Interest on the variable debt obligations under the Term Loan with Comerica Bank is calculated at 3.25%, the interest rate in effect as of March 31, 2011.

(4) Interest on the variable debt obligation under the credit facilities with Deerfield is calculated at 7.5%, the interest rate in effect as of March 31, 2011.

We are obligated under non-cancelable operating leases for all of our facilities and to a limited degree, equipment leases. Original lease terms for our facilities in effect as of March 31, 2011 were five to 10 years and generally require us to pay the real estate taxes, certain insurance and other operating costs. Equipment lease terms generally range from three to five years.

Purchase obligations totaling \$12.3 million are for outsourced services for clinical trials and other research and development costs. Purchase obligations totaling \$3.0 million are for software related expenses. The remaining \$1.7 million is for all other purchase commitments.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Market risk represents the risk of loss that may impact our financial position, results of operations or cash flows due to adverse changes in financial and commodity market prices and fluctuations in interest rates. Following the disposition of our remaining ARS in the quarter ended March 31, 2011, we no longer have liquidity risk associated with our ARS/marketable securities. All of our collaboration agreements and nearly all purchase orders are denominated in U.S. dollars. As a result, historically and as of March 31, 2011, we have had little or no exposure to market risk from changes in foreign currency or exchange rates.

Our investment portfolio is comprised primarily of readily marketable, high-quality securities diversified and structured to minimize market risks. We target our average portfolio maturity at one year or less. Our exposure to market risk for changes in interest rates relates primarily to our investments in marketable securities. Marketable securities held in our investment portfolio are subject to changes in market value in response to changes in interest rates and liquidity. A significant change in market interest rates could

Table of Contents

have a material impact on interest income earned from our investment portfolio. A theoretical 100 basis point change in interest rates and security prices would impact our annual net loss positively or negatively by \$758 thousand based on the current balance of \$75.8 million of investments classified as cash and cash equivalents and short-term and long-term marketable securities available for sale.

As of March 31, 2011, we had \$141.8 million of debt outstanding, exclusive of the debt discount of \$24 million. The term loan under our senior secured Term Loan with Comerica Bank of \$15 million is variable rate debt. Assuming constant debt levels, a theoretical change of 100 basis points on our current interest rate of 3.25% on the Comerica debt as of March 31, 2011 would result in a change in our annual interest expense of \$150 thousand. The interest rate on our long-term debt under the credit facilities with Deerfield is variable based on our total cash, cash equivalents and marketable securities balances. However, as long as our total cash, cash equivalents and marketable securities balances remain above \$60 million, our interest rate is fixed at 7.5%. Assuming constant debt levels, a theoretical change of 100 basis points on our current rate of interest of 7.5% on the Deerfield credit facilities as of March 31, 2011 would result in a change in our annual interest expense of \$1.2 million.

Historically and as of March 31, 2011, we have not used foreign currency derivative instruments or engaged in hedging activities.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer, Chief Financial Officer and other senior management personnel, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this Quarterly Report on Form 10-Q (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based on this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that our disclosure controls and procedures as of March 31, 2011 were effective to provide a reasonable level of assurance that the information we are required to disclose in reports that we submit or file under the Securities Act of 1934 (i) is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms; and (ii) is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure. Our disclosure controls and procedures are designed to provide reasonable assurance that such information is accumulated and communicated to management. Our disclosure controls and procedures include components of our internal control over financial reporting. Management's assessment of the effectiveness of our disclosure controls and procedures is expressed at a reasonable level of assurance because an internal control system, no matter how well designed and operated, can provide only reasonable, but not absolute, assurance that the internal control system's objectives will be met.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended March 31, 2011 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Table of Contents

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None

ITEM 1A. RISK FACTORS

Investing in our common stock is subject to a number of risks and uncertainties. We have updated the following risk factors to reflect changes during the quarter ended March 31, 2011 we believe to be material to the risk factors set forth in our Annual Report on Form 10-K for the fiscal year ended June 30, 2010 filed with the Securities and Exchange Commission. The risks and uncertainties described below are not the only ones that we face and are more fully described in our Annual Report on Form 10-K and in other reports we file with the Securities and Exchange Commission. Additional risks and uncertainties not presently known to us or that we currently believe are immaterial also may negatively impact our business.

Risks Related to Our Business

We have a history of operating losses and may not achieve or sustain profitability.

We have incurred significant operating and net losses and negative cash flows from operations since our inception. As of March 31, 2011, we had an accumulated deficit of \$525.4 million. We had net losses of \$11.5 million and \$34.6 million for the three and nine months ended March 31, 2011, respectively. We had net losses of \$77.6 million, \$127.8 million and \$96.3 million, for the fiscal years ended June 30, 2010, 2009 and 2008, respectively. We expect to incur additional losses and negative cash flows in the future, and these losses may continue or increase in part due to anticipated levels of expenses for research and development, particularly clinical development, expansion of our clinical and scientific capabilities, and acquisitions of complementary technologies or in-licensed drug candidates. As a result, we may not be able to achieve or maintain profitability.

Moreover, if we do achieve profitability, the level of any profitability cannot be predicted and may vary significantly. Much of our current revenue is non-recurring in nature and unpredictable as to timing and amount. While several of our out-licensing and collaboration agreements provide for royalties on product sales, given that none of our drug candidates have been approved for commercial sale, that our drug candidates are at early stages of development and that drug development entails a high degree of risk of failure, we do not expect to receive any royalty revenue for several years, if at all. For the same reasons, we may never realize much of the milestone revenue provided for in our out-license and collaboration agreements. Similarly, drugs we select to commercialize ourselves or partner for later-stage co-development and commercialization may not generate revenue for several years, or at all.

Because we rely on a small number of collaborators for a significant portion of our revenue, if one or more of our major collaborators terminates or reduces the scope of its agreement with us, our revenue may significantly decrease.

A relatively small number of collaborators account for a significant portion of our revenue. Amgen, Novartis, Celgene and Genentech accounted for 37%, 22%, 21% and 20%, respectively, of our total revenue for the first nine months of fiscal 2011; and 20%, 0%, 28% and 48%, for the first nine months of the prior year, respectively. We expect that revenue from a limited number of collaborators, including Celgene, Genentech, Amgen and Novartis, will account for a large portion of our revenue in future quarters. In general, our collaborators may terminate their contracts with us upon 60 to 180 days' notice for a number of reasons. In addition, some of our major collaborators can determine the amount of products delivered and research or development performed under these agreements. As a result, if any

Table of Contents

one of our major collaborators cancels, declines to renew or reduces the scope of its contract with us, our revenue may significantly decrease.

We may not be successful in entering into additional out-license agreements on favorable terms, which may adversely affect our liquidity or require us to change our spending priorities on our proprietary programs.

We are committing significant resources to create our own proprietary drug candidates and to build a commercial-stage biopharmaceutical company. We have built our clinical and discovery programs through spending \$444.8 million from our inception through March 31, 2011. During the first nine months of fiscal 2011 we spent \$44.2 million in research and development for proprietary programs. In fiscal 2010, we spent \$72.5 million in research and development for proprietary programs, compared to \$89.6 million and \$90.3 million for fiscal years 2009 and 2008, respectively. Our proprietary drug discovery programs are in their early stage of development and are unproven. Our ability to continue to fund our planned spending on our proprietary drug programs and in building our commercial capabilities depends to a large degree on up-front fees, milestone payments and other revenue we receive as a result of our partnered programs. To date, we have entered into six out-licensing agreements for the development and commercialization of our drug candidates, and we plan to continue initiatives during fiscal 2011 to partner select clinical candidates to obtain additional capital. We may not be successful, however in entering into additional out-licensing agreements with favorable terms, including up-front, milestone, royalty and/or license payments and the retention of certain valuable commercialization or co-promote rights, as a result of factors, many of which are outside of our control. These factors include:

- Our ability to create valuable proprietary drugs targeting large market opportunities;
- Research and spending priorities of potential licensing partners;
- Willingness of and the resources available to pharmaceutical and biotechnology companies to in-license drug candidates to fill their clinical pipelines;
- The success or failure, and timing, of pre-clinical and clinical trials for our proprietary programs we intend to out-license; or
- Our ability or inability to generate proof-of-concept data and to agree with a potential partner on the value of proprietary drug candidates we are seeking to out-license, or on the related terms.

If we are unable to enter into out-licensing agreements and realize milestone, license and/or up-front fees when anticipated, it may adversely affect our liquidity and we may be forced to curtail or delay development of all or some of our proprietary programs, which in turn may harm our business and the value of our stock. In addition, insufficient funds may require us to relinquish greater rights to product candidates at an earlier stage of development or on less favorable terms to us or our stockholders than we would otherwise choose in order to obtain funding for further development and/or up-front license fees needed to fund our operations.

If we need but are unable to obtain additional funding to support our operations, we could be unable to successfully execute our operating plan or be forced to reduce our operations.

We have historically funded our operations through revenue from our collaborations and out-license transactions, the issuance of equity securities and debt financing. We used \$52.8 million for our operating activities in the first nine months of fiscal 2011. A portion of our cash flow is dedicated to the payment of interest under our existing senior secured Term Loan with Comerica Bank, and to the payment of principal and interest on our credit facilities with Deerfield. In addition, the principal amounts outstanding under the senior secured Term Loan and the Deerfield Credit Facilities becomes due and payable in 2013 and 2014, respectively. Our debt obligations could therefore render us more vulnerable to competitive pressures and economic downturns and impose some restrictions on our operations.

Table of Contents

Our current operating plan and assumptions could change as a result of many factors, and we could require additional funding sooner than anticipated. If we are unable to meet our capital requirements from cash generated by our future operating activities and are unable to obtain additional funds when needed, we may be required to curtail operations significantly or to obtain funds through other arrangements on unattractive terms, which could prevent us from successfully executing our operating plan. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of those securities would result in dilution to our stockholders.

Because our stock price may be volatile, our stock price could experience substantial declines.

The market price of our common stock has historically experienced and may continue to experience volatility. The high and low closing bids for our common stock were \$3.29 and \$2.70, respectively, for the third quarter of fiscal 2011; \$3.58 and \$2.98, respectively, for the second quarter of fiscal 2011; \$3.44 and \$2.67, respectively, during the first quarter of fiscal 2011; \$4.45 and \$1.72, respectively, during the fiscal 2010; \$8.79 and \$2.51, respectively, during fiscal 2009; and \$12.91 and \$4.66, respectively, in fiscal 2008. Our quarterly operating results, the success or failure of our internal drug discovery efforts, decisions to delay, modify or cease one or more of our development programs, negative data or adverse events reported on programs in clinical trials we or our collaborators are conducting, uncertainties about our ability to continue to operate as a going concern, changes in general conditions in the economy or the financial markets and other developments affecting our collaborators, our competitors or us could cause the market price of our common stock to fluctuate substantially. This volatility coupled with market declines in our industry over the past several years have affected the market prices of securities issued by many companies, often for reasons unrelated to their operating performance, and may adversely affect the price of our common stock. In the past, securities class action litigation has often been instituted following periods of volatility in the market price of a company's securities. A securities class action suit against us could result in potential liabilities, substantial costs and the diversion of management's attention and resources, regardless of whether we win or lose.

Health care reform, including those based on recently enacted legislation and cost control initiatives by third-party payors could reduce the prices that can be charged for drugs, which could limit the commercial success of our drug candidates.

In March 2010, the President signed the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010, together the Healthcare Reform Act. These laws substantially change the way health care is financed by both governmental and private insurers and significantly impacts the pharmaceutical industry. The Healthcare Reform Act contains a number of provisions that will be expected to impact our business and operations, in some cases in ways we cannot currently predict. Changes that may affect our business include those governing enrollment in federal healthcare programs, mandatory discounts on pharmaceuticals under federal health care programs, reimbursement changes and fraud and abuse enforcement. These changes will impact existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program.

Additional provisions of the Healthcare Reform Act, some of which become effective in 2011, may negatively affect any associated product revenues and prospects for continued profitability in the future. For example, the Healthcare Reform Act imposes a non-deductible excise tax on pharmaceutical manufacturers or importers that sell branded prescription drugs to U.S. government programs that may impact any associated product revenue and therefore revenue we are entitled to receive from royalties on product sales. In addition, as part of the Healthcare Reform Act's provisions closing a funding gap that currently exists in the Medicare Part D prescription drug program (commonly known as the donut hole), manufacturers of branded prescription drugs will be required to provide a 50% discount on drugs dispensed to beneficiaries within this donut hole. We expect that the Healthcare

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Reform Act and other healthcare reform measures that may be adopted in the future could have a material adverse effect on our industry generally and on the ability of Array or our collaborators to successfully commercialize product candidates or could limit or eliminate our future spending on development projects.

In addition to the Healthcare Reform Act, there will continue to be proposals by legislators at both the federal and state levels, regulators and third-party payors to keep healthcare costs down while expanding individual healthcare benefits. Certain of these changes could limit the prices that can be charged for drugs we develop or the amounts of reimbursement available for these products from governmental agencies or third-party payors, or may increase the tax obligations on pharmaceutical companies, increase our rebate liability and discount obligations and so may limit our commercial opportunity and reduce any associated revenue and profits. For example, federal laws require drug manufacturers to pay specified rebates to each state Medicaid program for medicines reimbursed by Medicaid and to provide discounts for out-patient medicines purchased by certain safety net providers and disproportionate share hospitals and for purchases by some federal governmental departments such as the Department of Veterans Affairs and the Department of Defense. The rebates paid to state Medicaid programs are based on pricing data reported by manufacturers on a monthly and quarterly basis to the Centers for Medicare and Medicaid Services, the federal agency which administers the Medicaid drug rebate program. These data include the average manufacturer price, or AMP, and in the case of innovator products, the best price for each drug. As a result of the enactment of the Healthcare Reform Act, rebates now also will be due on the utilization of Medicaid managed care organizations, effective March 23, 2010.

Table of Contents

Pursuant to the Healthcare Reform Act, the amount of the Medicaid rebate for each unit of a drug has been increased. For innovator products, in general a drug marketed under a new drug application, or NDA, the minimum rebate has been increased from 15.1% to 23.1% of the AMP for that product, or if it is greater, the difference between the AMP and the best price for the drug. The Medicaid rebate for innovator products also includes an additional rebate amount if price increases for the drug exceed the rate of inflation since the product's launch, and in the case of certain line extension products, the additional rebate can be tied to the price of the original version of the product. The Healthcare Reform Act also caps the total rebate amount for innovator drugs at 100% of the AMP for the drug. In addition, the Healthcare Reform Act and subsequent legislation enacted in August of 2010 change the definition of AMP. Regulations have not been adopted to implement any of the enacted statutory changes. There may be additional increases in rebates or other costs and charges from government agencies. Regulations continue to be issued and coverage expanded by various governmental agencies relating to these programs, increasing the cost and complexity of compliance.

Health reform also expanded the number of safety net providers and hospitals that receive discounted pricing on out-patient medicines. In some countries other than the U.S., reimbursement, pricing and profitability of prescription pharmaceuticals and biopharmaceuticals are subject to government control. We are unable to predict what additional legislation or regulation, if any, relating to the healthcare industry or third-party coverage and reimbursement may be enacted in the future or what effect such legislation or regulation would have on our business.

Also, we expect managed care plans will continue to put pressure on the pricing of pharmaceutical and biopharmaceutical products due to a trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative proposals. Cost control initiatives could decrease the price that we, or any potential collaborators, receive for any of our future products, which could adversely affect our profitability. These initiatives may also have the effect of reducing the resources that pharmaceutical and biotechnology companies can devote to in-licensing drug candidates and the research and development of new drugs, which could reduce our resulting revenue. Any cost containment measures or other reforms that are adopted could have a negative impact on our ability to commercialize successfully our products or could limit or eliminate our spending on development of new drugs and affect our profitability.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4. RESERVED

ITEM 5. OTHER INFORMATION

None

46

Table of Contents

ITEM 6. EXHIBITS

<u>Exhibit Number</u>	<u>Description of Exhibit</u>
31.1	Certification of Chief Executive Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
31.2	Certification of Chief Financial Officer pursuant to Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
32.1	Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Table of Contents

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado, on this 2nd day of May 2011.

ARRAY BIOPHARMA INC.

By: /s/ Robert E. Conway
Robert E. Conway
Chief Executive Officer

By: /s/ R. Michael Carruthers
R. Michael Carruthers
Chief Financial Officer
(Principal Financial and
Accounting Officer)